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Summary 
In the healthy individual fungal infections are relatively benign, however in the rapidly 
increasing population of immunosuppressed patients fungal infections have become an 
increasing cause of morbidity and mortality. In the response to fungal pathogens, the 
innate immune system recognises a series of specific PAMPs via the Dectin-1 and TLR2 
receptors, ultimately resulting in pro and anti-inflammatory cytokine production.  
 
Following Dectin-1 activation, I show that blocking SYK activity with SYK inhibitor II 
prevents MAPK and NFκB signalling, causing a reduction in both pro and anti-
inflammatory cytokine production. However, the clinically used inhibitor R406 
(fostamatinib), which has been described as a SYK inhibitor, does not block these 
signalling pathways downstream of Dectin-1 activation, but is able to abolish cytokine 
production. As R406 has these effects in response to not only Dectin-1 ligand stimulation, 
but also TLR2 and TLR4 stimulation, it is likely that these events are the result of an off 
target effect of R406, and not a result of SYK inhibition. In line with this, R406 was 
found to inhibit multiple kinases in an in vitro kinase screening panel. 
 
To investigate signalling further downstream of Dectin-1, I attempted to elicit the kinase 
responsible for ERK1/2 activation. For most stimuli, Raf-1 activates MEK1/2 which 
activates ERK1/2, however in response to TLR signalling the kinase Tpl2 is required to 
activate MEK1/2. I show that the kinase responsible for ERK1/2 activation downstream 
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of Dectin-1 is not Tpl2, but is an unidentified off target effect of the Tpl2 small molecule 
inhibitor SHN681. 
 
MSK1 and 2 have previously been shown to be important in limiting inflammatory 
cytokine production by macrophages in response to the TLR4 agonist LPS.  This is in 
large part due to the ability of MSKs to regulate the production of the anti-inflammatory 
cytokine IL-10.  In this thesis I show that MSKs are activated in macrophages by fungal 
ligands, including the Dectin-1 specific agonists curdlan and depleted zymosan, via the 
ERK1/2 and p38α MAPK pathways. Further, I show that although MSKs regulate 
Dectin-1 induced IL-10 transcription, this does not significantly affect pro-inflammatory 
cytokine production. This is in direct contrast to the inhibition of these pro-inflammatory 
cytokine that we see post LPS stimulation. Investigating further, I show that although IL-
10 secreted in response to zymosan is unable to suppress pro-inflammatory cytokine 
production, it is still able to promote STAT3 phosphorylation. I suggest that Gfi1 is 
involved as I show that LPS can induce high levels of Gfi1 expression, whereas zymosan 
does not induce Gfi1. One possible explanation would be that without Gfi1 to inhibit 
PIAS3, PIAS3 is binding the activated STAT3 and not allowing it to bind to DNA. This 
would result in STAT3 being unable to function, and hence no repression of pro-
inflammatory cytokine expression would occur, regardless of the level of IL-10 present.  
 
Finally, I show that activation of Dectin-1 in a SYK dependent fashion resulted in 
macrophage switching to a regulatory macrophage phenotype. As regulatory 
macrophages are thought of as essentially anti-inflammatory, this may help explain why 
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many people suffer commensal fungal infections that can persist for long periods of time 
without developing the classical inflammatory signs of infection. 
 
  
 19
1. Introduction 
1.1 The Immune System – An Overview 
The body is protected from infectious agents and pathogens by its immune system. To be 
effective the immune system must have components that recognise a potential pathogen, 
effector cells that combat the pathogen and an immunological memory to ensure rapid 
recognition and elimination in future encounters. There must also be the ability for the 
immune system to self-regulate, to prevent auto-immunity. 
 
The human immune system comprises of two main components – the innate immune 
system and the adaptive system. The cells of the innate immune system include 
macrophages, dendritic cells (DCs) and neutrophils, all of which are programmed to be 
able to detect invariant features of invading pathogens. Innate immune responses occur 
rapidly on exposure to pathogen. The adaptive immune system comprises T lymphocytes 
and B lymphocytes. These cells employ non-germ line encoded receptors which allows 
very specific pathogen recognition. However, it means that their response although much 
more efficient at pathogen elimination than the innate system can take days to generate. A 
subset of previously activated lymphocytes can last long after an initial infection has been 
combated, and hence are capable of generating immunological memory (Iwasaki and 
Medzhitov 2010).  
 
In this thesis I will focus mainly on the response of the innate immune system to fungal 
pathogens. 
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1.2 Pattern Recognition Receptors 
Recognition of a pathogen is the first step in a body’s defence against infection. In the 
innate immune system, this is achieved through germ-line encoded pattern recognition 
receptors (PRRs) that recognise highly conserved microbial patterns known as Pathogen 
Associated Molecular Patterns (PAMPs).  
 
PRRs can be divided into secreted, cytosolic and transmembrane receptors. Secreted 
PRRs bind to pathogens, activate the complement system and opsonise pathogens for 
phagocytosis by macrophages and neutrophils. Cytosolic PRRs, for example RIG-I-like 
helicases, detect viral pathogens by responding to foreign DNA and foreign RNA, and 
NOD like receptors that detect microbial pathogens and stress signals. Transmembrane 
PRRs, examples of which include Toll-like receptors (TLRs) and C-type lectins, are 
expressed on plasma membranes and recognise PAMPs that are available on the 
pathogens cell surface. Transmembrane receptors, notably TLRs, can also be expressed 
on endosomal, phagosomal and lysosomal membranes where they can detect the presence 
of many foreign ligands including DNA, RNA and components of pathogen cell walls 
(Iwasaki and Medzhitov 2010).  
 
1.3 Fungal Infection 
Fungal infections in healthy individuals are relatively benign, but in the 
immunocompromised they are a major source of morbidity and mortality (Warnock 
2007). This at risk population includes patients undergoing treatment for malignancies or 
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autoimmune conditions, recipients of solid organ or haematopoetic stem cell transplants, 
people with human immunodeficiency virus (HIV), burns patients and individuals whom 
have long-term indwelling medical devices.  
 
Over the last 30 years the number of cases of invasive fungal infections has risen 
dramatically. This is largely due to the decreasing mortality of those who are chronically 
immunosuppressed, notably with improved treatments for HIV, the increasing success of 
organ transplantation, and more intensive treatments for autoimmune diseases resulting in 
dramatic prolonged immunosuppression (Warnock 2007).  
 
1.4 The Innate Response to Fungal Infection 
In the innate response to fungal pathogens, there are a number of PRRs that are 
potentially involved. These include the Toll-like receptors (TLRs), the C-type lectin 
receptors, the mannose receptor and the complement receptor 3 (Brown 2006).  
β-glucan is a major constituent of fungal cell walls, and following the discovery that 
Dectin-1 was a major β-glucan receptor on macrophages (Brown and Gordon 2001), 
many strategies were undertaken to determine the relative significance of each PRR in the 
recognition of fungal pathogens and the effect on cellular signalling. This was initially 
through the use of zymosan, a reagent prepared from Saccharomyces cerevisiae, which 
predominately contains β-glucan and mannan (Di Carlo and Fiore 1958), as a model 
fungal stimulus. Later the Dectin-1 specific ligand depleted zymosan (Ikeda, Adachi et al. 
2008) and the purified β-1,3glucan curdlan were also used.  
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Results following the use of a Dectin-1 neutralising antibody and Dectin-1 knock out 
mouse strengthened the evidence for the role of Dectin-1 in the recognition of the β-
glucan in zymosan by primary macrophages (Brown, Taylor et al. 2002). TLR2 has also 
been shown to be heavily involved in the response to zymosan.  
 
1.5 C-type Lectin Receptors  
The C-type lectin receptor family comprises a large group of proteins that all contain a 
conserved carbohydrate recognition domain that provides a highly variable interface for 
binding carbohydrate structures (Drickamer 1989).  
 
The C-type lectin receptor family is divided into 17 groups based on phylogeny and 
domain organisation, and although the C-type lectin family were described originally for 
their calcium dependent lectin activity, it has since been shown that many members of 
this family do not require calcium nor bind carbohydrate ligands (Zelensky and Gready 
2005) 
 
Despite all family members containing the highly conserved carbohydrate recognition 
domain, the C-type lectin receptors are all functionally diverse with roles in cell adhesion, 
complement activation, pathogen recognition and phagocytosis (reviewed in (Kerrigan 
and Brown 2010). Several C-type lectin receptors including Dectin-1, Dectin-2, MINCLE 
(macrophage-inducible C-type lectin) and the mannose receptor are involved in innate 
anti-fungal immunity.  
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1.5.1 Dectin-1 
Dectin-1 is a C-type lectin type II transmembrane receptor that was first discovered as a 
dendritic cell-specific receptor that interacted with T cells (Ariizumi, Shen et al. 2000). 
Dectin-1 is highly expressed on neutrophils, inflammatory macrophages and alveolar 
macrophages, with lower expression on resident macrophages and DCs (Taylor, Brown et 
al. 2002). It has also been shown to be present on B-cells, although its exact role here is 
not clear (Willment, Marshall et al. 2005). Dectin-1 is the predominant macrophage 
receptor for β-glucan (Brown and Gordon 2001), and with β-glucan being essential for 
maintaining fungal cell structure integrity, it can comprise up to 50% of the fungal cell 
wall (Calderone and Braun 1991). 
 
1.5.2 Dectin-1 Knock Out Mouse  
Dectin-1 knockout mice are viable with no apparent phenotype exhibited when they are 
maintained in specific pathogen free conditions. Several groups have now reported the 
response of the Dectin-1 knockout mouse to in vivo fungal infections. When exposed to 
Pneumocystis carinii they showed an early impairment in lung clearance, but ultimately 
cleared the organism as well as wild type mice (Saijo, Fujikado et al. 2007). On exposure 
to Cryptococcus neoformans the Dectin-1 deficient mice did not differ in their response 
from wild type mice. However, on exposure to Aspergillus fumigatus, the deficient mice 
were unable to produce significant pro-inflammatory cytokines, and had delayed fungal 
clearance, lower neutrophil lung recruitment and ultimately severe lung dysfunction 
rapidly leading to death (Werner, Metz et al. 2009). 
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The outcome following infection with the common fungi Candida albicans is less clear, 
with the literature split in favour of Dectin-1 being required for protection against 
disseminated candidiasis (Taylor, Tsoni et al. 2007), and there being no difference in 
susceptibility to Candida albicans infection between the Dectin-1 deficient and wild type 
mice (Saijo, Fujikado et al. 2007). A likely explanation for this difference is that the two 
groups used different strains of C.albicans to inoculate the mice (Drummond and Brown 
2011). Another likely conflicting factor is the fact that both groups have made their own 
Dectin-1 knockout mice on different mouse backgrounds. Thus, so far mouse studies 
have not been able to give a clear role for Dectin-1 in candidiasis.  
 
1.5.3 Mutations in Human Dectin-1 
In 2009, the first functional Dectin-1 polymorphism was reported in a Dutch family 
whom suffered with chronic or recurring onychomycosis or recurrent vulvovaginal 
candidiasis (Ferwerda, Ferwerda et al. 2009). The authors found that 3 sisters all have a 
homozygous single nucleotide polymorphism within Dectin-1 (rs16910526, exon 6, 
chromosome 12). The mutation is an A to C base change within the carbohydrate 
recognition domain (CRD) of Dectin-1, and results in a change of amino acid 238 from 
tyrosine to a stop codon (Tyr238X). This mutation truncates the CRD by 9 amino acids. 
Macrophages taken from individuals with this mutation expressed very low levels of the 
Dectin-1 receptor on the cells surface, and that the macrophages were almost 
unresponsive to β-glucans, producing a very impaired cytokine response. However, these 
patients’ neutrophils were still able to phagocytose and kill C.albicans as normal, which 
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explains why these patients only suffer from onychomycosis and vulvovaginal 
candidiasis, and do not develop invasive fungal infections (Ferwerda, Ferwerda et al. 
2009).  
 
Subsequently, a cohort of patients with haematological malignancies was studied 
(Plantinga, van der Velden et al. 2009), and it was found that patients who were 
heterozygous for the Dectin-1 Tyr238X mutation were more likely to be colonised with 
C.albicans (oral and gastrointestinal) than patients without this polymorphism. 
Surprisingly, the presence of the Dectin-1 polymorphism did not result in higher 
incidence of systemic candidiasis, but this maybe explained by the routine use of 
fluconazole to eradicate colonisation in these high risk patients. Additionally, there were 
no patients who were homozygous for the Dectin-1 mutation in this cohort. However, 
macrophages from the heterozygous patients showed a significant decrease in Dectin-1 
receptor expression on the cell surface compared to the wild type macrophages 
(Plantinga, van der Velden et al. 2009); hence heterozygosity for the mutation does have 
functional significance. This study again shows that adequate Dectin-1 receptors are 
necessary to prevent colonisation of mucosal surfaces by Candida, but are not necessary 
in the prevention of disseminated invasive candidiasis.  
 
1.5.4 Other C-type Lectin Receptors 
The other main C-type lectin receptors involved in the innate immune response to fungi 
are Dectin-2, MINCLE (macrophage-inducible C-type lectin) and the mannose receptor 
(illustrated in figure 1).  
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Dectin-2 is a type II transmembrane receptor that is predominately expressed on tissue 
macrophages and inflammatory monocytes, recognising high mannose structures 
contained in many fungal pathogens (McGreal, Rosas et al. 2006). Dectin-2 has a very 
short cytoplasmic domain, lacking any obvious signalling motif, and so once activated 
must associate with the FcRγ adaptor, which contains an ITAM, to then enable signalling, 
which occurs via the SYK-CARD9 pathway (Sato, Yang et al. 2006; Bi, Gojestani et al. 
2010). Dectin-2 knock out mice showed virtually no cytokine production in response to 
fungal α-mannan, and the yeast forms of C.albicans induced IL-1β and IL-23 secretion in 
a Dectin-2 dependent manner (Saijo, Ikeda et al. 2010). This suggests that Dectin-2 is 
important in detecting and responding to the less immuno-vigorous yeast forms of fungus 
that Dectin-1 is less able to detect.  
 
MINCLE is a type II transmembrane protein that is upregulated once a macrophage 
becomes activated, primarily recognising fungal α-mannan and mycobacterial cord factor 
(Matsumoto, Tanaka et al. 1999). Like Dectin-2, MINCLE has a very short cytoplasmic 
tail and so must also associate with the FcRγ adaptor in order to signal through the SYK-
CARD9 pathway (Yamasaki, Ishikawa et al. 2008). Primary macrophages from MINCLE 
knockout mice showed reduced production of pro-inflammatory cytokines, notably TNF-
α, in response to C.albicans (Wells, Salvage-Jones et al. 2008). In vivo, the MINCLE 
knock out mice show a significantly increased susceptibility to systemic candidiasis 
(Wells, Salvage-Jones et al. 2008). 
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The mannose receptor is a type I transmembrane protein that is expressed predominately 
by macrophages, both within the endocytic pathway and in a released soluble form as a 
cytosolic receptor. The mannose receptor has a wide variety of ligands such as terminal 
mannose, sulphated sugars, frucose, glucosamine and a number of endogenous proteins, 
and as such can induce a range of cellular responses depending on the exact stimuli. To 
date, the mechanisms of intracellular signalling downstream from the mannose receptor 
have not been elucidated. Mannose receptor knockout mice show no increase in 
susceptibility to infection by C.albicans (Lee, Zheng et al. 2003).  
 
 
 
Figure 1 Illustration of the C-type Lectin Receptors Involved in the Innate Response to Fungi. 
Adapted from (Dostert and Tschopp 2007) 
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1.5.5 CARD9 Knockout Mouse  
The caspase-recruitment domain protein 9 (CARD9) has been shown to be essential for 
the propagation of signalling downstream of the C-type lectin receptors, as detailed later 
in section 1.8. CARD9 knockout mice have been generated which are viable with no 
apparent phenotype exhibited when they are maintained in specific pathogen free 
conditions (Gross, Gewies et al. 2006). The CARD9 deficient mice were shown not to 
have any defect within T- and B-cell differentiation and activation for adaptive immunity. 
In response to the bacterial pathogen Staphylococcus aureus the CARD9 knockout mice 
cleared the infection as effectively as the wild type mice. However, the CARD9 knockout 
mice showed significantly increased susceptibility to infection by Candida albicans, with 
significantly increased mortality rates and massively increased fungal burdens in the 
kidneys, liver and lungs when compared to wild type mice (Gross, Gewies et al. 2006). 
 
1.5.6 Mutations in Human CARD9 
DNA analysis from 36 members of a large consanguineous Iranian family identified a 
homozygous mutation in exon 6 of CARD9 that results in a loss of function mutation due 
to a premature stop codon (Q295X) in the coding sequence. All of the homozygous 
individuals had recurrent oropharyngeal and/or vulvovaginal candidiasis, and 2 members 
of the family had previously developed fatal meningeal candidiasis (Glocker, Hennigs et 
al. 2009). This suggests that the CARD9 mutation confers a stronger phenotype that the 
Dectin-1 mutation, which could be in part due to the fact that CARD9 also relays signals 
from other C-type lectin receptors. However, when comparing these studies we must bear 
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in mind the consanginuity of the Iranian family and as such other genetic defects may 
have contributed to the more severe phenotype seen. 
 
1.6 Toll-Like Receptors 
Toll-like receptors (TLRs) are probably the most studied of all the PRRs. The receptor 
protein Toll was first identified in Drosophila meglanogaster as the gene that was 
responsible for controlling dorso-ventral patterning in the embryo (Anderson, Bokla et al. 
1985). It was noted that activation of the Toll receptor by its ligand (Spatzle) activated a 
signalling cascade which ultimately activated Dorsal, the Drosophila version of the 
mammalian NFκB (reviewed in (Qureshi and Medzhitov 2003). In 1996 it was 
discovered that mutations in Drosophila Toll resulted in the inability of adult flies to 
defend against fungal pathogens (Lemaitre, Nicolas et al. 1996). Subsequently, homologs 
of Toll, called Toll-like receptors, have been found in mammals. The first indication that 
TLRs were important in mammalian immunity came from studies looking at two LPS 
resistant strains of mice, C3H/HeJ and C57/10ScCr (Poltorak, He et al. 1998). Poltorak et 
al found that the mouse strain C3H/HeJ had a missense mutation in the third exon of the 
TLR4 gene, resulting in the replacement of proline by histidine at position 712 of the 
polypeptide chain, and that C57/10ScCr mice were homozygous for a null mutation of 
TLR4, hence providing the first evidence that a functional TLR4 is required to recognise 
LPS (Poltorak, He et al. 1998).  
 
To date there have been 13 TLRs described, 10 of which (TLR1-10) are expressed in 
humans, and 12 of which (TLR1-9 and TLR11-13) are expressed in mice (Kawai and 
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Akira 2010).  All TLRs are type 1 transmembrane glycoprotein receptors, and each TLR 
recognises a distinct set of evolutionarily conserved PAMPs that are not found in healthy 
vertebrate cells (Akira, Uematsu et al. 2006), these are summarised in table 1.  
 
The first TLR knockout mouse described was the TLR4 knockout mouse. The authors 
showed that macrophages deficient in TLR4 were unable to activate NFκB and failed to 
produce any detectable TNFα in response to LPS stimulation (Hoshino, Takeuchi et al. 
1999). Following this, the TLR2 knockout mouse was produced. The TLR2 deficient 
mice responded to LPS to the same level as wild type mice, but were hyporesponsive to 
peptidoglycan, a major constituent of Gram positive bacteria cell wall (Takeuchi, 
Hoshino et al. 1999). TLR2 knockout mice are highly susceptible to infection by the 
Gram positive bacteria Staphlococcus aureus, being able to produce significantly less 
cytokines than the wild type (Takeuchi, Hoshino et al. 2000).  
 
Regarding the TLR knockout mouse response to fungal pathogens, it is reported that 
neither the TLR2 nor the TLR4 knockout mice were more susceptible to infection by 
Aspergillus fumigatus than the wild type mice (Dubourdeau, Athman et al. 2006). 
Further, TLR2 and TLR4 knockout mice both respond as wild type mice following 
infection with Cryptococcus neoformans (Nakamura, Miyagi et al. 2006). In response to 
Candida albicans there was no difference in susceptibility to primary candidiasis in the 
TLR2 knockout mice when compared to wild type, however interestingly the TLR4 
knockout mice did show increased susceptibility to infection (Bellocchio, Montagnoli et 
al. 2004). However, in conflict to this, it has also been reported that the TLR2 knockout 
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mice are also more susceptible to Candida albicans than wild type mice (Netea, van der 
Graaf et al. 2002). 
 
 The individual TLR knockout mice results are confounding. It is possible that when one 
TLR has been knocked out another may compensate, and so another way to investigate 
the role of TLRs in fungal infection is to look at the MyD88 knockout mice. TLR 
signalling is discussed later in section 1.8.3, however MyD88 is an essential component 
for signalling downstream of all TLRs, with the exceptions of TLR3 and TLR4, and 
without it there can be no compensation from other MyD88 signalling TLRs. The MyD88 
knockout mice consistently show that they are more susceptible than the wild type to 
infections by Candida (Bellocchio, Montagnoli et al. 2004) (Marr, Balajee et al. 2003). 
The effect of the MyD88 knockout in response to Aspergillus fumigatus differs greatly 
with reports varying from showing no difference in susceptibility to infection in the 
knockouts (Marr, Balajee et al. 2003; Bellocchio, Montagnoli et al. 2004), to delayed 
clearance of Aspergillus  (Bretz, Gersuk et al. 2008), through to failure to produce any 
pro-inflammatory response in the MyD88 knockout mice (Mambula, Sau et al. 2002). 
These reports are conflicting and many factors are likely to be contributing, such as 
differences in the sources of the animals, the exact preparation of fungus used and the 
time scales of studies.   
  
In humans, screening of groups with candidiasis has shown that TLR2 mutation 
Arg753Gln is a risk factor for Candida sepsis (Woehrle, Du et al. 2008), and that TLR1 
polymorphisms resulting in impaired function of TLR1 are associated with decreased 
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cytokine responses and an increased susceptibility to candidemia (Plantinga, Johnson et 
al. 2012). All studies however are very small and struggle to reach statistical significance.  
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Table 1 TLR Receptors and Their Ligands 
Toll-Like Receptor Specific Ligands 
TLR1:TLR2 
heterodimer 
Bacterial lipoproteins (Triacylated lipoproteins from Gram 
negative bacteria) 
TLR2 Peptidoglycan and Lipoteichoic acids (Gram positive bacteria) Lipomannans (fungi and mycobacteria) 
TLR2:TLR6 
heterodimer 
Bacterial lipoproteins (Diacylated lipopeptides from Gram 
positive bacteria) 
TLR3 Double-stranded RNA (viruses) 
TLR4 Lipopolysaccharide (LPS) (a cell wall component of Gram negative bacteria) 
TLR5 Flagellin (element of bacterial flagella) 
TLR7 Single-stranded RNA (viruses) 
TLR8 Single-stranded RNA (viruses) 
TLR9 DNA with non methylated CpG (bacteria and herpes viruses) 
TLR10 Unknown 
TLR11 (mouse only) Profilin and Profilin-like proteins (uropathogenic bacteria) 
TLR12 (mouse only) Unknown 
TLR13 (mouse only) Unknown 
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1.7 Dectin-1 and TLR Synergy 
Dectin-1 and TLR2 can act synergistically, and produce a larger cytokine and pro-
inflammatory response than that achieved by either receptor individually (Gantner, 
Simmons et al. 2003; Ferwerda, Meyer-Wentrup et al. 2008). It is suggested that Dectin-1 
enhances the TLR2 signal via a CARD9 dependent mechanism, as it is shown that 
CARD9 deficient bone marrow derived macrophages (BMDM) have a defect in TNFα 
production following zymosan stimulation (Goodridge, Takahiro et al. 2009). 
 
The relative contribution of Dectin-1 versus TLR2 in the in vivo response to Aspergillus 
fumigatus has been extensively studied. As detailed earlier, the Dectin-1 knockout mouse 
in response to A. fumigatus was unable to produce significant pro-inflammatory 
cytokines, and had delayed fungal clearance (Werner, Metz et al. 2009). The role of 
Dectin-1 is supported by a further study using a soluble Dectin-1 fusion protein to block 
Dectin-1 in alveolar macrophages. By blocking Dectin-1 the authors saw a reduction in 
pro-inflammatory cytokine levels and an increase in fungal burden (Steele, Rapaka et al. 
2005). In TLR2 knockout mice, the authors saw a minimal reduction in pro-inflammatory 
cytokines in response to A. fumigatus, with only a slight reduction in TNFα production 
showing statistical significance (Steele, Rapaka et al. 2005). This enhancing, but not 
essential, role of TLR2 in the macrophage response to A. fumigatus is supported by the 
data from the MyD88 knockout mice. TLR2 requires MyD88 to signal following 
activation, and hence MyD88 knockout is another useful way to remove the TLR2 
contribution. The MyD88 knockout removes all input from the other MyD88 signalling 
TLRs (that is all but TLR3 and TLR4), and so removes the possibility of any 
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compensation from other TLRs that might be seen in the TLR2 only knockout. It is 
reported that the MyD88 knockout mouse, in response to A. fumigatus, shows increased 
fungal burden, delayed lung clearance and delayed resolution of inflammation (Bretz, 
Gersuk et al. 2008). It is therefore apparent that for optimum macrophage inflammatory 
response to A. fumigatus you require Dectin-1, but the potentially redundant pathway of 
TLR2 is important for mediating the inflammatory response.  
 
Dectin-1 is reportedly the sole receptor on macrophages for β-glucans (Saijo, Fujikado et 
al. 2007); however, these glucans are not readily exposed on fungal hyphae but are seen 
predominantly at bud scars and on conidia (Gantner, Simmons et al. 2005). It has been 
suggested that through differential PRR recognition macrophages can tailor their immune 
response to the invasiveness of pathogen encountered. For example, in the response to 
Aspergillus fumigatus, macrophages bind and ingest the resting conidia effectively 
without activating Dectin-1 and with little inflammatory response (Gersuk, Underhill et 
al. 2006). However, mature conidia and germ tubes do show a large amount β-glucan on 
their surface and as a result activate Dectin-1, resulting in large secretions of 
proinflammatory cytokines (Gersuk, Underhill et al. 2006). TLR2 also recognises the 
hyphal form of Aspergillus fumigatus, and whilst Dectin-1 binding is shown to only 
augment the TLR2 mediated IL-6 and IL-12 secretion in response to Aspergillus 
fumigatus, it is absolutely required for TNFα production (Gersuk, Underhill et al. 2006).   
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1.8 Signalling Downstream of Immune Receptors  
1.8.1 General Principles of Signalling 
The enzymes most commonly associated with receptor activation and intracellular 
signalling pathways are the protein kinases. Protein kinases are a large group of enzymes 
that catalyse the covalent attachment of a phosphate group to a protein. This is a 
reversible process, known as protein phosphorylation. Protein kinases can be divided into 
two main groups, tyrosine kinases which phosphorylate tyrosine residues, and 
serine/threonine kinases that phosphorylate either serine or threonine residues. An 
exception to this are the STE7 family, which can phosphorylate both threonine and 
tyrosine residues (Manning, Whyte et al. 2002).  
 
To allow this signal to be switched off, a group of enzymes called protein phosphatases 
are able to remove the phosphate group from phosphotyrosine or from 
phosphoserine/phosphotyrosine. This specific phosphorylation and dephosphorylation is 
critical to the regulation of signalling pathways and is a process that is used in many 
cellular systems as a way of controlling the activity of enzymes, transcription factors and 
many other proteins.  
 
1.8.2 ITAM Linked Signalling Pathway 
Many receptors of the immune system, notably the B-cell receptor (BCR), the T-cell 
Receptor (TCR), the Fc Receptor and some of the C-type lectin receptors, contain 
immunoreceptor tyrosine-based activation motifs (ITAMs) in their cytoplasmic tail. An 
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ITAM consists of a short amino acid sequence containing a duplicate of the sequence 
YxxL/I with 6 to 12 intervening residues. Each ITAM contains two tyrosine residues that 
become phosphorylated when the receptor binds to its ligand; this in turn allows the 
recruitment of signalling molecules that contain tandem SRC homology 2 domains 
(Underhill and Goodridge 2007).  
 
In macrophages, Dectin-1 is one of the receptors that signal through an ITAM-like motif 
(hemi-ITAM). Dectin-1 has an ITAM-like motif because the two tyrosines contained in 
its cytoplasmic tail are positioned in a similar fashion to those in an ITAM but the N-
terminal tyrosine resides in a YxxxL motif (YxxxI in mice), opposed to the ITAM 
sequence of YxxL (Kerrigan and Brown 2011). Ligand binding to the Dectin-1 receptor 
leads to phosphorylation of the ITAM-like domain which then associates with spleen 
tyrosine kinase (SYK) (Rogers, Slack et al. 2005).  
 
1.8.2.1 Spleen Tyrosine Kinase  
SYK is a 72kDa tandem SRC homology 2 domain-containing tyrosine kinase. SYK is 
best known for its role in signalling downstream of the classical immune receptors, 
notably the BCR, TCR and the Fc receptors (Mocsai, Ruland et al. 2010). However, SYK 
has been shown to mediate signalling by other receptors, including integrins (Mócsai, 
Zhou et al. 2002) and C-type lectins (Kerrigan and Brown 2010), and has been 
implicated in many non-immune roles, for example bone metabolism, platelet function 
and tumour suppression (reviewed in (Mocsai, Ruland et al. 2010). 
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 Despite its far reaching biological roles, SYK has perhaps been most studied 
downstream of the BCR. Stimulation of the BCR causes cross-linking of the receptors, 
activating the membrane bound src-family tyrosine kinases, Fyn, Blk and Lyn. These 
kinases then in turn phosphorylate the ITAMs on the cytoplasmic tails of Igα and Igβ, 
which recruit and activate SYK. As there are usually many receptor complexes clustered 
together, many SYK molecules can be bound in close proximity, and are therefore able to 
further phosphorylate and activate each other to promote enhanced signalling. SYK can 
activate phospholipase C-γ (PLC-γ), which then cleaves phosphatidylinositol biphosphate 
(PIP2) into diacylglycerol (DAG) and inositol triphosphate (IP3). DAG then activates 
protein kinase C, small G proteins activate the MAPK cascade, and IP3 increases 
intracellular calcium activating calcineurin, which in turn activates nuclear factor of 
activated T-cells (NFAT). All of which ultimately controls the induction of specific 
cytokine gene transcription (reviewed in (Mocsai, Ruland et al. 2010). 
 
1.8.2.2 Dectin-1 Signalling Downstream of SYK 
As discussed, Dectin-1 phosphorylation upon ligand binding leads to a direct interaction 
between Dectin-1 hem-ITAM and SYK (Rogers, Slack et al. 2005). This is thought to 
initiate a signalling cascade that induces a scaffold comprising of the caspase-recruitment 
domain protein CARD9 with the adaptor proteins BCL10 and MALT1 (Goodridge, 
Takahiro et al. 2009). It has been shown that the CARD9-BCL10-MALT1 scaffold is 
required to activate the IkappaB kinase (IKK) complex, which ultimately leads to 
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activation of  transcription factors including NFκB, and ultimately cytokine production 
(Gross, Gewies et al. 2006).  
 
A second, unclear, signalling pathway occurs from SYK following Dectin-1 ligand 
binding– whereby SYK triggers reactive oxygen species generation, which in turn causes 
NLRP3 inflammasome activation (Gross, Poeck et al. 2009). This is necessary for the 
activation of caspase-1, which is then able to cleave pro-IL-1β to IL-1β allowing the 
cytokine to become active and secreted.  
 
A further signalling pathway has also been described whereby Dectin-1, independently of 
SYK, activated the serine-threonine kinase Raf-1. The researchers added a neutralising 
antibody to Dectin-1 or piceatannol to inhibit SYK. They showed that by adding antibody 
to Dectin-1 they could block Raf-1 phosphorylation, but Raf-1 was still able to be 
phosphorylated in the presence of piceatannol (Gringhuis, Dunnen et al. 2009). This 
implies that Dectin-1 is capable of activating Raf-1 independently of SYK.  This pathway 
was supported by data using RNA-mediated interference to suppress Raf-1, which 
showed that without Raf-1 the expression of IL-10, IL-12 (p40), IL-6 and IL-1β was 
decreased (Gringhuis, Dunnen et al. 2009).  
 
The role of MAP kinase signalling downstream of Dectin-1 is not yet fully understood. It 
has been shown that ERK1/2 activation in response to zymosan is independent of the 
TLR2/MyD88 pathway (Slack, Robinson et al. 2007) and that ERK1/2 inhibition reduces 
the amount of IL-10 produced in response to zymosan (Dillon, Agrawal et al. 2006). It 
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has not been demonstrated as yet whether ERK1/2 is activated, as TLRs are, by Tpl2, or 
by Raf-1 downstream of Dectin-1.  
 
1.8.2.3 Genetic Loss or Inhibition of SYK   
The systemic loss of SYK is perinatally lethal due to defects in endothelial cells within 
the vasculature, and so therefore it is not possible to study adult total SYK deficient mice. 
Instead, the effect of SYK deficiency in haematopoeic cells has been primarily studied 
following the reconstitution of irradiated mice with SYK knockout foetal liver cells. This 
has shown that the absence of SYK causes failure of B-cell maturation and the total loss 
of immune receptor signalling (Cheng, Rowley et al. 1995; Turner, Mee et al. 1995). 
Conditional SYK knockout mice have been made, using Cre recombinase to 
conditionally delete SYK in the myeloid cells only. In these mice, it has been shown that 
in vitro SYK deficient neutrophils are unable to secrete cytokines and generate reactive 
oxygen species, and in vivo the SYK bone marrow chimera mice have significant 
impairment in their ability to successfully kill Staphlococcus aureus (Van Ziffle and 
Lowell 2009). However, the conditional mice seem to be protected from the development 
of autoimmune conditions, as they are shown to be more resistant to the development of 
autoantibody induced experimental arthritis, with the ability to block both macroscopic 
and microscopic signs of arthritis (Jakus, Simon et al. 2010).  
 
In humans, rheumatoid arthritis (RA) has been associated with autoantibodies directed 
against antigens such as type II collagen and heat shock proteins in addition to the 
ubiquitous rheumatoid factor, which recognises the Fc fragment of IgG (Steiner and 
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Smolen 2002). It is therefore not surprising that these immune complexes lead to 
inflammatory cytokine release within joints, causing further synovitis and ultimately 
further joint destruction. As these autoantibody immune complexes are abnormal, they 
stimulate the Fc receptors on various haematopoietic cells. The activated Fc receptors 
contain an ITAM motif which when phosphorylated activates SYK, resulting in cytokine 
gene expression and an inflammatory response (Braselmann, Taylor et al. 2006). SYK 
inhibitors are therefore a potential therapeutic target for preventing inflammation in 
rheumatoid arthritis. The only current clinical SYK inhibitor R788, also known as 
fostamatinib disodium, (prodrug of the active metabolite R406), has been shown to 
reduce the severity of autoimmune arthritis in mouse models (Braselmann, Taylor et al. 
2006; Pine, Chang et al. 2007). Following this, a 12 week randomised placebo-controlled 
pilot human study was undertaken in people with active RA despite methotrexate therapy. 
A significant benefit was seen by the first week in those patients taking R788, with 
significant decreases in IL-6 and a marked improvement in symptoms (Weinblatt, 
Kavanaugh et al. 2008). A second randomised placebo controlled trial was undertaken in 
a cohort of patients that had refractory RA, that is had failed all treatments including 
biological agents such as anti-TNF therapy, anakinra, abatacept and/or rituximab. In this 
refractory cohort there was no difference between the R788 treatment and placebo groups 
(Genovese, Kavanaugh et al. 2011). This is not entirely surprising as it is likely that such 
severe and unresponsive arthritis has many multi-factorial inflammatory driving 
processes. Large phase III trials with R788 in RA are currently underway.  
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To date there have been 5 phase II clinical studies using R788, and although RA 
represents the most numerous and notable clinical studies (totally 3 of the 5), it has also 
been trialled in other autoimmune diseases, with phase II trial success in the treatments of 
autoimmune thrombocytopenia and lymphoma (McAdoo and Tam 2011). 
 
1.8.3 TLR Activation and Signalling 
The TLRs can be divided into three groups according to the adaptor proteins they 
associate with upon activation. There are 4 different adaptor proteins used by mammalian 
TLRs: Myeloid differentiation factor 88 (MyD88), MyD88 adaptor-like (MAL), TIR 
domain containing adaptor-inducing IFN-β (TRIF) and TRIF-related adaptor molecule 
(TRAM). TLRs 5, 7, 8 and 9 all interact with the adaptor protein MyD88 alone. TLR2 
requires MyD88 and MAL. TLR3 interacts only with TRIF, whilst TLR4 is in the unique 
position of interacting with both MyD88/MAL and TRIF/TRAM complexes (reviewed in 
(Kawai and Akira 2010). Interactions of TLRs with TRIF leads to the generation of both 
a type I interferon response and inflammatory cytokines, whereas MyD88 signalling 
alone induces primarily inflammatory cytokines (McCoy, Macdonald et al. 2007). 
 
1.8.3.1 The MyD88 Dependent Pathway 
After ligand binding to their TLRs, MyD88 recruits and activates the IL-1 receptor 
associated kinases IRAK4 and IRAK1/2, which then associate with the ubiquitin E3 
ligase tumour necrosis factor receptor-associated factor 6 (TRAF6). It has been shown 
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that IRAK4 is absolutely required for activation of MAPKs and NFκB, whereas IRAK1 
and 2 are only required for optimal activation of MAPKs and NFκB (Kawagoe 2008). 
Once IRAK-1 is active, it somehow activates TRAF6 E3 ligase, causing TRAF6 to then 
ubiquitinate itself and IKKγ (also known as Nemo). This creates a polyubiquitin scaffold 
bringing TAK1 into close proximity to the IKK complex, allowing TAK1 to activate the 
IKKβ, ultimately resulting in activation of NFκB (Bhjo and Chen 2009). TAK1 can also 
phosphorylate MKK3/6 and MKK4/7, resulting in the activation of p38 and JNK 
respectively (Figure 2). 
 
TLR signalling also results in the activation of the MAPKs ERK1 and 2 via the MAP3K 
Tpl2. In unstimulated cells, Tpl2 is held in an inactive complex with ABIN2 and the 
NFκB subunit p105. Following IκB kinase (IKK) induced degredation of p105, active 
Tpl2 is released which then via MEK1/2 activates ERK1/2 (Waterfield, Zhang et al. 
2003). It has been shown in Tpl2 knockout mice studies that Tpl2 is absolutely required 
for the activation of ERK1 and 2 by LPS, and that Tpl2/ERK activation are essential for 
TNFα induction in response to LPS (Dumitru, Ceci et al. 2000). 
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Figure 2 A Diagrammatic Representation of the TLR/MyD88 Dependent Signalling Pathways. 
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1.8.3.2 The TRIF Dependent Pathway 
Interaction of TLR3 and TLR4 with TRIF leads to the generation of both a type I 
interferon response and inflammatory cytokines. Ligand binding to the TLR3 or TLR4 
receptor causes recruitment of TRIF. Via its death domain, TRIF activates IKKε and 
TBK1 (Fitzgerald, McWhirter et al. 2003). This leads to phosphorylation of the 
transcription factor IRF3, which then induces IFNβ. In addition Trif can also activate the 
NFκB and MAPK signalling pathways (Yamamoto, Sato et al. 2002; Kawai and Akira 
2008).  
 
1.8.4 MAPK Signalling 
In the immune system, MAPK signalling is pivotal in linking inflammatory stimuli to 
cellular outcome. MAPKs cascades consist of at least three tiers of kinases, MAPKs are 
activated by MAPK kinases (MAP2K), which are in turn activated by MAPK kinase 
kinase (MAP3K) that are activated by MAPK kinase kinase kinase (MAP4K) (figure3). 
This specificity allows the MAPK cascades to be involved in many diverse and specific 
cellular roles. The three major MAPK pathways are the classical MAPKs ERK1 and 2, 
p38 and JNKs (Raman, Chen et al. 2007).  
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Figure 3 Schematic Representation of the MAPK Cascades.  
Adapted from (Roux and Blenis 2004) 
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1.8.5 Mitogen and Stress Activated Protein Kinases 
Both Dectin-1 and TLR2 signalling result in the activation of the p38α and ERK1/2 
MAPK pathways. This might be expected to lead to the activation of the mitogen and 
stress activated protein kinase (MSK) 1 and 2 (McCoy, Macdonald et al. 2007). MSKs 
are nuclear protein kinases that have been shown to be activated by both ERK1/2 and p38 
in a variety of cell types. In macrophages MSKs have been shown to phosphorylate 
CREB, ATF1 and histone H3 in response to TLR agonists (Ananieva, Darragh et al. 
2008), and as a result MSKs are able to regulate the transcription of specific immediate 
early genes. As discussed below, it is known that MSK1/2 can affect both pro-
inflammatory and anti-inflammatory cytokine production.  
 
1.8.5.1 MSK1/2 Knockout Mouse 
Our laboratory has previously shown that when TLR4 is stimulated by LPS, mice lacking 
the MSK1/2 proteins show a significant increase in the production of pro-inflammatory 
cytokines TNFα, IL-6 and IL-12 relative to wild type (Ananieva, Darragh et al. 2008). 
There is no difference between wild type and knockout macrophages in their production 
of IL-1. However, the MSK1/2 knockout macrophages do show a decrease in their 
production of the pro-resolution factors IL-10 and DUSP1. It was shown that the lack of 
MSK1/2 prevents the activation of CREB and ATF1 which would, in normal 
circumstances, induce the transcription of DUSP1, a MAPK phosphatase which 
inactivates p38 and JNK. Via the phosphorylation of CREB, MSKs also increase IL-10 
expression (Ananieva, Darragh et al. 2008). IL-10 is known to be a strong anti-
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inflammatory cytokine which inhibits the production of pro-inflammatory cytokines by 
macrophages through the activation of the Janus kinase-STAT3 transcription factor 
signalling. IL-10 does not inhibit pro-inflammatory cytokines without STAT3 (Williams, 
Bradley et al. 2004), and in response to LPS the MSK1/2 knockout mice show not only 
much lower levels of IL-10, but much less phosphorylation of STAT3. This supports the 
theory that the excessive inflammatory response seen in the MSK1/2 knockout mice is 
due in part to the lack of IL-10 (Ananieva, Darragh et al. 2008). 
 
In an attempt to characterise the in vivo response to TLR4 stimulation in the MSK1/2 
deficient mice our laboratory previously took two approaches (Ananieva, Darragh et al. 
2008). The first was to cause endotoxic shock in the mice through intraperitoneal 
injections of LPS. As expected, the MSK1/2 knockout mice were more sensitive, 
succumbing to endotoxic shock far more rapidly than their wild type counterparts. The 
second approach was to actually cause a bacterial infection by perforating the caecum and 
inducing peritonitis. Interestingly, in this setting of exposure to potentially virulent 
pathogens, the MSK1/2 knockout mice had a much higher survival rate than the wild type 
mice. It is suggested that the MSK1/2 knockout mice’s massive pro-inflammatory 
cytokine response is protective in the setting of live pathogen infection, as the excessive 
inflammatory response is more effectively and rapidly destroying the pathogen, and once 
eliminated the inflammation can resolve. 
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1.9 IL-10 Signalling 
IL-10 was first described as a cytokine produced by Th2 T helper cell clones that 
inhibited cytokine production by Th1 T helper cells (Fiorentino, Bond et al. 1989).The 
regulatory nature of IL-10 in controlling the macrophage inflammatory response was first 
reported when it was observed that IL-10 inhibited the production of pro-inflammatory 
cytokines IL-6, IL-1 and TNFα by LPS activated macrophages (Fiorentino, Zlotnik et al. 
1991). Since then much research has focused on how exactly IL-10 exerts its anti-
inflammatory effect, although the full mechanism has not yet been fathomed. In 
macrophages, it is understood that following TLR signalling IL-10 is secreted by 
macrophages, and that the secreted IL-10 feeds back, binding to the IL-10 receptor and 
activating the Janus kinase 1 (JAK1) (Rodig, Meraz et al. 1998), which in turn recruits 
and activates STAT3 (signal transducer and activator of transcription 3). The activation 
of STAT3 initiates the anti-inflammatory process, and it has been shown that STAT3 is 
essential for the repression of inflammation by IL-10 (Williams, Bradley et al. 2004). The 
mechanism of action of STAT3 is not fully understood, although it is thought not to act 
directly to reduce inflammatory cytokines, but instead to work via other, as yet unknown, 
genes.  
 
The IL-10 knockout mouse clarifies the necessity of IL-10 in modulating and regulating 
the macrophage immune response. When challenged by bacterial pathogens IL-10 
knockout mice mount massive inflammatory responses, producing huge unregulated 
amounts of IL-12 and TNFα (Gazzinelli, Wysocka et al. 1996), and are highly 
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susceptible to LPS induced toxic shock (Berg, Kuhn et al. 1995). Further, the IL-10 
deficient mice can spontaneously develop chronic enterocolitis, which is though to be 
driven by resident gut flora (Kuhn, Lohler et al. 1993). 
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2. Aims 
 Using a variety of ligands, inhibitors and genetically altered macrophages examine 
the differences between Dectin-1 and TLR signalling on cytokine production in 
macrophages. 
 
 To examine the activation of ERK1/2 downstream of Dectin-1 in macrophages. 
 
 To investigate the role of MSK1/2 in the response to fungal stimuli, whether via 
Dectin-1 or TLR2 activation, and the consequences on inflammation and cytokines in 
macrophages. 
 
 To investigate the role of IL-10 in the suppression of pro-inflammatory cytokines in 
response to fungal stimuli in macrophages. 
 
 To examine the differences between LPS and zymosan stimulation on macrophages. 
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3. Materials and Methods 
3.1 Materials 
All chemicals unless otherwise stated were obtained from Sigma or VWR. All solutions 
were prepared using deionised water (MilliQ system, Millipore) and where appropriate 
solutions were autoclaved at 120oC, 15psi for 20mins.  
 
3.2 Common Solutions  
Phosphate Buffered Saline (PBS)   37mM NaCl  
2.7mM KCl 
4.3mM Na2HPO4 
1.2mM KH2PO4 
 
 
5x Sample Buffer     250mM Tris-HCL pH 6.8 
        32.5% (v/v) Glycerol 
        5% (w/v) SDS 
5% (v/v) 2-β-mercaptoethanol 
 
 
SDS Lysis Buffer     80% (v/v) Triton Lysis Buffer 
10% (v/v) Glycerol 
1% (w/v) SDS  
0.1 % (v/v) 2- β-mercaptoethanol 
Bromophenol blue to colour 
 
 
SDS-PAGE Running Buffer    25mM Tris 
192mM Glycine 
0.1% (w/v) SDS 
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SDS-PAGE Separating Gel       0.375M Tris-HCL pH8.6 
10% or 12% (w/v) 29:1 
Acrylamide:Bis- Acrylamide 
0.01% (w/v) SDS 
0.034% ammonium persulphate 
0.08% (v/v) Temed 
 
 
SDS-PAGE Stacking Gel    0.124M Tris-HCl pH6.8 
3.73% (w/v) 29:1 Acrylamide:Bis-
Acrylamide 
0.01% (w/v) SDS 
0.085% ammonium persulphate 
0.1% (v/v) Temed 
 
 
Transfer buffer     48mM Tris 
39mM Glycine 
20% (v/v) Methanol 
 
 
Tris Buffered Saline and Tween (TBS-T)  50mM Tris pH 7.5 
150mM NaCl 
0.1% (v/v) Tween-20 
 
 
Triton Lysis Buffer     50 mM Tris-HCl pH 7.5 
1 mM EDTA 
1mM EGTA 
1% (v/v) Triton X-1000 
1 mM Sodium Orthovanodate 
50 mM Sodium Fluoride 
5 mM Sodium Pyrophosphate 
10 mM Sodium β-Glycerophosphate 
0.27M Sucrose 
0.1 % 2-β-Mercaptoethanol  
1x protease inhibitor tablet (Roche) 
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3.3 Animals 
MSK1/2 knockout mice and IL-10 knockout mice have been previously described (Kuhn, 
Lohler et al. 1993; Wiggin, Soloaga et al. 2002), and had been backcrossed onto a 
C57BL/6 background for at least 12 generations. CREB Ser133Ala knockin mice 
(described in (Wingate, Martin et al. 2009) were backcrossed onto a C57BL/6 
background for at least 6 generations. Dectin-1 knockout femurs were obtained from 
Professor Gordon Brown (University of Aberdeen), and were on a 129/Sv genetic 
background (Taylor, Tsoni et al. 2007). All mice were maintained in specific pathogen 
free conditions, and in line with United Kingdom and European Union regulations. Work 
was approved by local ethical review and was carried out under the authority of a Home 
Office project license.  
 
All routine animal care and biopsies were undertaken by the staff of the Transgenic Unit, 
University of Dundee. All mouse colony maintenance and breeding was organized by Dr. 
Arthur. All PCR genotyping of mouse biopsies was undertaken by Julia Carr (MRC 
Protein Phosphorylation Unit, University of Dundee). 
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3.4 Cell Culture 
3.4.1 Derivation and Culture of BMDMs 
Bone marrow derived macrophages (BMDMs) were derived from adult mice. After 
culling, the femurs were removed under sterile conditions. In a tissue culture hood the 
femurs were placed in bacteriological grade dishes and sterile PBS was used to flush the 
bone marrow from the femurs. The bone marrow suspension was then passed through a 
100µm cell strainer into a 50ml falcon tube and centrifugated at 900 rpm for 5 minutes. 
The supernatant was aspirated and the pellet resuspended in 20ml of media (DMEM 
(Gibco) with 10% FBS (Biosera, heat inactivated), 5mg/ml L-Glutamine (Gibco), 5% 
antibiotic-antimycotic (Gibco) and 5ng/ml Macrophage Colony Stimulating Factor (R&D 
Systems). The media/cell suspension was then divided between 2 x 10cm bacteriological 
grade culture plates. The cells were then incubated at 37°C in 5% CO2 for seven days.  
 
On day seven, the dishes containing the macrophages are removed from incubator and the 
media aspirated. Each dish was washed with 5ml of sterile PBS. 5ml of versene (Gibco) 
was added, and the cells incubated for 10 minutes to loosen cell adhesions. The cells were 
then removed with a sterile cell scraper and centrifuged at 1000 rpm for 5 minutes. The 
supernatant was aspirated and the pellet resuspended in 12ml of media (as above). This 
was then divided into 2ml per well of a 6 well plate, or 1ml per well of a 12 well plate 
dependent on the experimental use of the BMDMs (cell density 2x105 cells/ml). The cells 
were incubated overnight and stimulated the following day. 
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3.4.2 RAW264.7 Macrophage-Like Cell Line 
RAW264.7 cells are a mouse macrophage cell line obtained from the American Type 
Culture Collection (Manassas, U.S.A.). They are an adherent cell line that were 
maintained in DMEM (Gibco) supplemented with 10% FBS (Sigma, heat inactivated), 
5% L-Glutamine (Gibco) and 5% penicillin-streptomycin (Gibco). They were maintained 
in an incubator at 37°C in 5% CO2. The day prior to use, the cells were scrapped into the 
media and then spun down at 1000 rpm for 5 minutes. The cells were then resuspended in 
fresh media and plated onto 6 or 12 well plates. The cells were incubated overnight and 
stimulated the following day. 
 
3.4.3 A20 B-cell Lymphoma Mouse Cell Line 
The A20 cell line is a mature mouse B-cell lymphoma cell line that expresses a mature B-
cell receptor. We were kindly donated the cells by Dr Sharon Matthews, University of 
Dundee. The A20 cells are semi-adherent and as such are maintained at a density of 
between 1x105 and 1x106 cells per ml in RMPI 1640 media (Gibco), supplemented with  
10% heat inactivated FBS (Sigma, heat inactivated), 5% L-Glutamine (Gibco), 5% 
penicillin-streptomycin (Gibco) and 50µM 2-β-mercaptoethanol, and were incubated at 
37°C in 5% CO2. The day prior to use, the adherent cells were scrapped into the media 
and then spun down at 1000 rpm for 5 minutes. The cells were then resuspended in fresh 
media and plated onto 10cm plates. The cells were incubated overnight and stimulated 
the following day. 
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3.5 Stimulation and Inhibition of Cells 
3.5.1 BMDM Stimulation 
The BMDMs were stimulated with a range of microbial ligands, as indicated in the figure 
legends. These were zymosan (Sigma) used at 200µg/ml, depleted zymosan (Invivogen) 
used at 200µg/ml and curdlan (Sigma) used at 10µg/ml. LPS (from E. Coli 055:B5, 
Sigma) was used at 100ng/ml, Pam3CSK4 (Invivogen) was used at 1µg/ml, Poly(I:C) 
(Invivogen) was used at 10 µg/ml and CpG (Invivogen) was used at 2µM. Recombinant 
mouse IL-10 (R&D Systems) was used at 100ng/ml. In some experiments, BMDMs were 
treated with beads to simulate phagocytosis of fungal particles; these were Estapor 
microsphere 0.8µm latex calibrated particles from Merck.  
 
3.5.2 A20 Cell Stimulation 
The A20 cells were stimulated via their B-cell receptor, to ensure SYK dependent 
signalling pathway activation. For this I used F(ab’)2 fragment rabbit anti-mouse IgG 
(Jackson ImmunoResearch Laboratories) at a concentration of 10µg/ml to cross-link the 
BCR and simulate antigen stimulation.  
 
3.5.3 Inhibitors 
The BMDMs were inhibited with a range of small molecule inhibitors. The MEK 
inhibitor PD184352 and the p38 inhibitor SB203580 were used at 2µM and 5µM 
respectively. The Tpl2 inhibitor Compound 1 (also known as SHN681) was used at 
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10µM. The IKK inhibitor BIX02514 was used at 10µM. The COX2 inhibitor NS398 was 
used at 10µM. All of these inhibitors were from the DSTT, University of Dundee, either 
being synthesised by the team, or purchased from Calbiochem. These concentrations all 
correspond to those previously established in the laboratory as being the minimum 
required to inhibit the target kinase in cells. 
 
The SYK inhibitors I, II, III and IV were all purchased from Calbiochem. R406 was 
purchased from American Custom Chemical Corporation. Piceatannol was purchased 
from both Sigma and Calbiochem. The SYK inhibitors were all used at varying 
concentrations as stated.  
 
3.5.4 Neutralising Antibodies 
The Dectin-1 neutralising antibody was a rat IgG monoclonal antibody to murine dectin-1 
(Invivogen, clone 2A11) and was used at 10µg/ml. Isotype rat antibody (R&D systems) 
was used at 10µg/ml as a control. 
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3.6 Lysis of Cells for RNA 
After stimulation of cells, the media was removed and frozen at -80ºC for later cytokine 
analysis. The remainder of the media was aspirated. The cells were then washed with 
sterile PBS and 350µl of Qiagen RLT buffer with 1% β-mercaptoethanol was then added 
per well. The cells were disrupted with a cell scraper and then transferred to a Qiagen 
QIAshredder column. The lysate column was then centrifuged at 13000 rpm for 2 
minutes. The column and lysate were then frozen to store at -80 ºC. When required, the 
lysate were defrosted and total RNA was extracted using the Qiagen RNeasy micro kit 
following the manufacturer’s instructions. The RNA was eluted in 14µl of RNase free 
water and stored at -80 ºC. 
 
3.7 Determination of RNA Concentration and Reverse 
Transcription  
1.4µl of purified RNA was quantified using the nanodrop machine (Thermo Scientific), 
as per the manufacturer’s instructions. Absorbance at 260nm was read, and the sample 
concentration determined by the nanodrop software. 0.7µg of RNA was then diluted into 
10µl of nuclease free water, and added to 4µl of iscript reaction mix (Bio-Rad) and 1µl of 
iscript reverse transcriptase (Bio-Rad). The samples were then reverse transcribed by 
incubating at 25ºC for 5 min, 42ºC for 30 min and finally 85ºC for 5 min. 200µl of 
nuclease free water was added to the cDNA. The cDNA was frozen at -20ºC until 
required. 
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3.8 Quantitative PCR  
3.8.1 Methodology 
Quantitative PCR was performed in 96 or 384 well plates (Bio-Rad) using SYBR green 
based detection system (Bio-Rad SsoFast EvaGreen supermix) with a Bio-Rad CXF 96 or 
Bio-Rad CXF 384 thermal cycler. Each reaction comprised 10µl SYBER green supermix, 
3.4µl nuclease free water, 0.8µl 10µM sense primer, 0.8µl 10µM antisense primer and 
5µl of cDNA. The plate was then sealed with optical tape (Bio-Rad), and cycled 95°C for 
30 sec to initially denature, followed by 40 cycles at 60°C for 25 sec, 95°C for 1 min, 
then 65°C for 1 min. Each sample was performed in duplicate. 18s ribosomal RNA 
values were used for normalisation. The relative mRNA levels were calculated using the 
following equation: 
 
Relative mRNA level =  Eu (ct uc – ct us) 
       Er (ct rc-ct rs) 
 
Where E is efficiency of PCR, Ct is the threshold cycle, u is the mRNA of interest, r is 
the 18s ribosomal RNA, s is the sample and c is the unstimulated control. 
 
3.8.2 Primers 
All primers were designed using the Beacon Designer 7.0 software programme and 
custom synthesised by Invitrogen. The primers were reconstituted in nuclease free water 
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at a concentration of 100µM, and then diluted to a working solution of 10µM as required. 
All primers were stored at -200C and aliquots of working stock were defrosted to room 
temperature prior to use. Amplification of the correct product was confirmed by members 
of our laboratory through cloning and sequencing of the PCR product. The sequences for 
all primers used are shown in table 2. 
 
3.9 Multiple Cytokine Secretion Assay 
Following cell stimulation for mRNA analysis, the media from the cells was stored at  
-80°C. When appropriate, the media was thawed and cytokine concentrations in the cell 
media were detected using the Luminex-based Bio-plex mouse cytokine 5-Plex and 9-
Plex panels (Bio-Rad) as per manufacturer’s instructions. 
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Table 2 Primer Sequences Used for Quantitative PCR 
Primer Name Sense Primer Anti-sense Primer 
18s  GTAACCCGTTGAACCCCATT  
CCATCCAATCGGTAGTAGCG 
 
Arg-1 CTCCAAGCCAAAGTCCTTAGAG AGGAGCTGTCATTAGGGACATC 
c-fos CTACTGTGTTCCTGGCAATAGC  
AACATTGACGCTGAAGGACTAC 
 
c-jun CGCCTCGTTCCTCCAGTC  
ACGTGAGAAGGTCCGAGTTC 
 
COX2 AATATCAGGTCATTGGTGGAGAGG TCAGACCAGGCACCAGACC 
Dusp-1 CCACAGGACACCGCACAAG  
AGCGAAGAAGGAGCGACAATC 
 
EBI-3 GCCGCTCCCCTGGTTA CAATGAAGGACGTGGATCTGGTC 
Egr-1 ACAGAAGGACAAGAAAGCAGAC  
CCAGGAGAGGAGTAGGAAGTG 
 
Egr-3 TGTGATGGACATCGGTCTGAC  
GGCACCAGTTGGAAGGAGAG 
 
Fos-b CCAGGGTCAACATCCGCTAAG  
GGTGAGGACAAACGAGGAAGTG 
 
G-CSF TGCACCCTGACTGGAGTTAC TGAAATCTCGATGTGTCCACAG 
GFI-1 GGTCCCAAACACTGATG  
CAACTGGTCCGTTATCC 
 
GFI-1 
unspliced  
TTGTAGGAGATGCTTGAA 
 
TTGACATAGAGGAAGATACT 
 
GFI-1b TCTAGTGAAGAGTAAGAAGG  
CTGTTTGATTGTGTTCCA 
 
GM-CSF CTACTGATAGGGACCATTA  
GGTAAGACATTCTCAATAAATAG 
 
Interferon β GGAAAAGCAAGAGGAAAGATTGAC CCACCATCCAGGCGTAGC 
Interferon γ AGCCAAGACTGTGATTGC  
TTATTGGTCAGTGAAGTAAAGG 
 
IL-1a TCAAGCAACGGGAAGATTC  
TATCTCAAATCACTCTGGTAGG 
 
IL-1b GACGGACCCCAAAAGATGAAGG  
GTGATACTGCCTGCCTGAAGC 
 
IL-1ra (total) TTACAAGGACCAAATATCAAACTAGAAG  
GGATGCCCAAGAACACACTATG 
 
IL-1ra 
(cytoplasmic) 
TCCTTTATACACAGCAAGTCTC 
 
TTCTGAAGGCTTGCATCTTG 
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IL-1ra 
(secretory) 
AGTCGCTAGTCTCTATTGCC 
 
TTCTGAAGGCTTGCATCTTG 
 
IL-2 CCCAAGCAGGCCACAGAATTG  
CTCATCATCGAATTGGCACTCAAATG 
 
IL-4 CTTGATAAACTTAATTGTCTCTC  
AATGCCGATGATCTCTC 
 
IL-6 TTCCATCCAGTTGCCTTCTTG  
AGGTCTGTTGGGAGTGGTATC 
 
IL-10 CCCTTTGCTATGGTGTCCTTTC  
GATCTCCCTGGTTTCTCTTCCC 
 
IL-12a TATCTCTATGGTCAGCGTTCC  
TGGTCTTCAGCAGGTTTCG 
 
IL-12b TCATCAGGGACATCATCAAACC  
TGAGGGAGAAGTAGGAATGGG 
 
IL-13 ACAAAGCAACTGTTTCG  
AGTCTGATGTGAGAAAGG 
 
IL-23A (p19) ATCCAGTGTGAAGATGGTTGTGAC TCCTAGTAGGGAGGTGTGAAGTTG 
IL-27 GAGGAGGACAAGGAGGAAGAGG GGGAGTGAAGGAGCTGGTAGC 
Light CTGCATCAACGTCTTGGAGA GATACGTCAAGCCCCTCAAG 
Mir132 CGGTGACTCAGCCTAGATGG GGACGGGACAGGGAAGGG 
Nor1 GCCATCTCCTCCGATCTGTATG  
GAGGCCGTCAGAAGGTTGTAG 
 
Nur1 GAAGAGAGCGGACAAGGAGATC  
AAGGCATGGCTTCAGCAGAG 
 
Nur77 CCTGTTGCTAGAGTCTGCCTTC  
CAATCCAATCACCAAAGCCACG 
 
SBNO2 AATGCCTCTGTCTTCTC  
GTGACTGATAGCTGATGA 
 
SerpinB2 CTGGATGAAGATGATGTTGTGGTC  
GAAGAATGGACTTGAGTTCGTAGC 
 
SPHK1 ACAGCAGTGTGCAGTTGATGA GGCAGTCATGTCCGGTGATG 
SOCS3 AGAAGATTCCGCTGGTACTGAG  
AAAGATGCTGGAGGGTGGC 
 
Jun-b TGCACGAAAATGGAACAGCC  
GGTGGGTTTCAGGAGTTTGTAG 
 
NFIL-3 TTCAGGACTACCAGACAT  
TGCTTGATGACTGAGATG 
 
TNFα CAGACCCTCACACTCAGATCATC  
GGCTACAGGCTTGTCACTCG 
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3.10 Detection of Protein by Immunoblotting 
3.10.1 Lysis of Cells for Protein for Immunoblotting 
After stimulation of cells, the media was aspirated. The cells were then washed with 
sterile PBS. 300µl of SDS lysis buffer was added to each well. The samples were heated 
to 97°C for 10 minutes, and then passed repeatedly through a 25 gauge needle to 
homogenise the sample. Samples were frozen at -20°C until required. 
 
3.10.2 Resolution of Protein Samples on SDS-Polyacrylamide Gel 
Electrophoresis (PAGE) 
For western blotting, 30µl of sample and 4µl of molecular weight standard marker (Bio-
Rad) were loaded on the SDS-PAGE gel. Self poured Tris-glycine gels were used with 
either 10% or 12% acrylamide with tris-glycine running buffer. The gels were then 
electrophoresed at 100V for 150-220 minutes. Proteins were then transferred onto 
nitrocellulose membrane.  
 
3.10.3 Transfer of Proteins onto a Nitrocellulose Membrane 
Bio-Rad transfer modules were used to transfer proteins from the SDS-PAGE gel onto 
the nitrocellulose membrane. All materials were pre-soaked in transfer buffer prior to 
assembly of transfer cassette. The transfer cassette comprised of 2 sponges, one 7.5cm by 
9cm 3mm filter paper, the SDS page gel, one 7.5cm by 8.5cm nitrocellulose membrane 
fully covering the gel, followed by a second piece of 3mm filter paper, and a further 
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sponge. The cassette was placed into a Bio-Rad tank, and the process repeated for a 
second gel and cassette. The tank was then filled to the top with transfer buffer, and an 
ice pack was added. The proteins were then transferred at 100V for 1hour. 
 
3.10.4 Western Blotting 
Following the transfer of proteins onto a nitrocellulose membrane, the membranes were 
then blocked with 5% dried milk/ tris-buffered saline with 0.1% tween (TBS-T) for 45 
minutes at room temperature on a shaker. The membranes were incubated with primary 
antibody diluted 1:1000 in either 5% dried milk/TBS-T or 5% bovine serum 
albumin/TBS-T overnight at 4oC. Table 3 shows a full list of all antibodies used. 
Unbound primary antibody was then removed by washing the membrane with TBS-T for 
3 x 10 minutes. Following this, the membranes were incubated in the appropriate 
horseradish conjugated secondary antibody (Pierce) diluted 1:2000 in 5% dried 
milk/TBS-T for 1 hour at room temperature. Unbound secondary antibody was removed 
by washing the membrane with TBS-T for 3 x 10 minutes. The signal was detected with 
enhanced chemiluminescence reagent (GE Healthcare). 
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Table 3 Antibodies Used for Western Blotting 
Antibody Isotype Company Order Number 
CREB Rabbit IgG Cell Signaling Technology #9197 
Phospho-CREB (Ser133) Mouse IgG1κ Millipore 05-667 
ERK1/2 Rabbit Polyclonal Cell Signaling Technology #9102 
Phospho-ERK1/2 
(Thr202/Tyr204) Rabbit Polyclonal Cell Signaling Technology #9101 
GAPDH Rabbit IgG Cell Signaling Technology #2118 
GFI-1 Rabbit Polyclonal Santa Cruz Biotechnology Sc-22796 
GFI-1B Goat Polyclonal Santa Cruz Biotechnology Sc-8559 
IκBα  
(Amino-terminal Antigen) Mouse IgG1 Cell Signaling Technology #4814 
IRF-3 Rabbit IgG Cell Signaling Technology #4302 
Phospho-IRF3 (Ser396) Rabbit IgG Cell Signaling Technology #4947 
JNK Rabbit Polyclonal Cell Signaling Technology #9258 
Phospho-JNK 
(Thr183/Tyr185) Rabbit Polyclonal Cell Signaling Technology #9251 
Phospho-MAPKAPK-2 
(Thr334) Rabbit Polyclonal Cell Signaling Technology #3041 
Phospho-MAPKAPK-2 Rabbit Polyclonal Cell Signaling Technology #3044 
MEK1/2 Rabbit Polyclonal Cell Signaling Technology #9122 
Phospho-MEK1/2 
(Ser217/221) Rabbit Polyclonal Cell Signaling Technology #9121 
MSK1 Sheep Polyclonal DSTT, University of Dundee N/A 
Phospho-MSK1 (Thr581) Rabbit Polyclonal Cell Signaling Technology #9595 
Phospho-MSK1 (Ser376) Rabbit Polyclonal Cell Signaling Technology #9591 
MyD88 Rabbit polyclonal Cell Signaling Technology #3699 
Phospho-NF-κB p65 
(Ser276) Rabbit polyclonal Cell Signaling Technology #3037 
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p38 MAPK Rabbit polyclonal Cell Signaling Technology #9212 
Phospho-p38 MAPK  
(Thr180/Tyr182) Rabbit polyclonal Cell Signaling Technology #9211 
Phospho-p90RSK (ser380) Rabbit polyclonal Cell Signaling Technology #9341 
STAT3 Rabbit polyclonal Cell Signaling Technology #9132 
Phospho-STAT1 (Tyr701) Rabbit polyclonal Cell Signaling Technology #9171 
Phospho-STAT3 (Ser727) Rabbit polyclonal Cell Signaling Technology #9134 
Phospho-STAT3 (Tyr705) Rabbit polyclonal Cell Signaling Technology #9131 
Phospho-STAT5 (Tyr694) Rabbit IgG Cell Signaling Technology #9359 
Phospho-STAT6 (Tyr641) Goat IgG Santa Cruz Biotechnology Sc-11762 
SYK Rabbit polyclonal Cell Signaling Technology #2712 
Phospho-SYK (Tyr323) Rabbit polyclonal Cell Signaling Technology #2715 
Phospho-SYK (Tyr525/526) Rabbit polyclonal Cell Signaling Technology #2711 
Phospho-SYK (Tyr352) 
/Phospho-ZAP-70 (Tyr319) Rabbit polyclonal Cell Signaling Technology #2701 
TBK1 Rabbit IgG Cell Signaling Technology #3504 
Phospho-TBK1 (Ser172) Rabbit IgG Cell Signaling Technology #5483 
Tpl2 Rabbit polyclonal Santa Cruz Biotechnology Sc-720 
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4. Results 
4.1 Dectin-1 Stimulation Activates MAPK Signalling Leading 
to MSK Activation and CREB Phosphorylation 
Dectin-1 is an important PRR for fungal pathogens. In order to study Dectin-1 signalling 
I made use of several ligands thought to act via either Dectin-1 alone or a combination of 
Dectin-1 and TLRs. Initially, I looked at the effect of fungal ligands on the signalling 
cascades in wild type BMDMs to ascertain which pathways were activated by fungal 
stimulation. To determine activation of a particular kinase, I used Western blotting to 
look at the phosphorylation status of the site known to be responsible for the activation of 
the kinase. For the MAPKs p38, ERK1/2 and JNK this was the TXY motif, which when 
phosphorylated causes the kinase to become active. For MSK1 Thr581 was used. This 
residue is phosphorylated by ERK1/2 or p38, resulting in activation of the C-terminal 
kinase domain in MSK1. This allows the C-terminal domain to phosphorylate and 
activate the N-terminal kinase domain which is responsible for the phosphorylation of 
substrates. I also looked at the phosphorylation of the transcription factors CREB and 
ATF1 which are substrates of MSK1.   
 
Zymosan is extracted from yeast cell wall and, based on the literature, I expected it to 
activate both TLR2 and Dectin-1 (Ikeda, Adachi et al. 2008). Wild type BMDMs were 
stimulated with zymosan alone, over a period of 6 hours, and Figure 4a shows that the 
three major MAPK pathways, ERK1/2, p38 and JNK were all activated by zymosan. In 
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addition, activation of MSK1 and phosphorylation of its substrates CREB and ATF1 were 
also observed. 
 
As zymosan stimulates both Dectin-1 and TLR2, the effects of depleted zymosan and 
curdlan, which are reported to be Dectin-1 specific, were examined (Figure 4b&c). This 
shows that both these stimuli also activated the classical MAPK pathways as well as 
MSK1 and CREB. Based on multiple experiments, zymosan was a stronger stimulus for 
MAPK signalling relative to either depleted zymosan or curdlan (data not shown).  
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Figure 4 Fungal Stimulation of Wild Type BMDMs.  
BMDMs were stimulated with a) 200µg/ml zymosan b) 10µg/ml curdlan c) 200µg/ml depleted zymosan 
and incubated for the stated times. Cells were lysed in 1% SDS lysis buffer and levels of the indicated 
proteins determined by immunoblotting. 
  
 
  a) Zymosan             b) Curdlan  c) Depleted Zymosan 
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4.2 The Examination of Dectin-1 Ligand Specificity 
To clarify whether depleted zymosan and curdlan only stimulate through Dectin-1 in 
BMDMs, a Dectin-1 neutralising antibody was used prior to stimulation. Figure 5 shows 
that the neutralising antibody prevented the activation of ERK1/2 and p38 by depleted 
zymosan, however, curdlan still activated these pathways despite the presence of the 
neutralising antibody.  
 
To confirm these results, BMDMs from Dectin-1 knockout mice were tested (Figure 6). 
Zymosan is still able to activate signalling pathways in the knockout BMDMs, as shown 
by the activation of p38 and ERK1/2, but this was reduced relative to the activation seen 
in wild type BMDMs. As NFκB is important in regulating cytokine production I also 
looked at phosphorylation of the p105 NFκB subunit. This is a substrate of the IKK 
complex and thus provides an indication of the activation of the canonical NFκB 
pathway, in addition to being required for Tpl2 activation. Like MAPK signalling, p105 
phosphorylation in response to zymosan was reduced in the Dectin-1 knockout. This is 
expected as zymosan can also stimulate TLR2 in addition to Dectin-1. Depleted zymosan 
was unable to activate MAPK or p105 signalling in the Dectin-1 knockout BMDMs, 
which is consistent with what was seen with the neutralising antibody. In line with this, 
MSK1 activation and CREB phosphorylation were also blocked. Curdlan was also unable 
to activate MAPK or p105 signalling pathways in the Dectin-1 knockout. This is in 
contrast to the neutralising antibody results that would suggest that curdlan should still 
signal in the Dectin-1 knockout. This maybe explained by the possibility that the Dectin-
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1 knockout is missing another crucial receptor, other than Dectin-1, that is required for, or 
contributes to, curdlan signalling as curdlan is a very crude ligand preparation. It is also 
possible that there is a flaw in the neutralising antibody experiments, for example a 
component of the curdlan solution may cause dissociation of the antibody from the 
receptor allowing Dectin-1 to be available for curdlan binding and activation of the 
receptor.   
 
Based on the Dectin-1 knockout, depleted zymosan and curdlan should not signal via 
TLR2. To confirm this I used BMDMs from MyD88 knockout mice, which are deficient 
in all MyD88 dependent TLR signalling (that is all TLRs with the exception of TLRs 3 
and 4). In line with this, figure 7 shows that the TLR2 agonist Pam3CSK4 did not induce 
p38, ERK1/2 or p105 phosphorylation in the MyD88 knockout macrophages. Curdlan, 
depleted zymosan and zymosan were all able to activate p38 and ERK1/2, as well as 
inducing p105 phosphorylation in the MyD88 knockout BMDMs. This is consistent with 
the activation of these pathways by Dectin-1, which does not associate with MyD88, by 
these stimuli. Interestingly however, curdlan activation of p38, ERK1/2 and p105 
phosphorylation in the MyD88 knockout BMDMs does appear to be reduced slightly 
when compared to the wild type. This implies that curdlan may also be able to signal 
independently of Dectin-1, but that this contribution is minimal, explaining why it was 
not obvious in the Dectin-1 knockout experiments. This finding also aids in the 
explanation of the neutralising antibody data, and is supported by very recent further 
work in our laboratory, which has shown that when curdlan is used at very high 
concentrations (200µg/ml), it can activate these signalling pathways independently of 
Dectin-1 (data not shown).
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Figure 5 Wild Type BMDMs Treated with Dectin-1 Neutralising Antibody, then Stimulated with 
Dectin-1 Ligands.  
BMDMs were pre-incubated for 1 hour with Dectin-1 neutralising antibody (10µg/ml) or isotype antibody 
(10µg/ml). BMDMs were then stimulated with either 200µg/ml of depleted zymosan or 10µg/ml of 
curdlan. BMDMs were incubated with the stimuli for 30 minutes; cells were then lysed in 1% SDS-lysis 
buffer and the levels of the indicated proteins were determined by immunoblotting. 
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Figure 6 Dectin-1 Wild Type and Knockout BMDMs.  
BMDMs stimulated with a) 200µg/ml zymosan b) 10µg/ml curdlan c) 200µg/ml depleted zymosan for the 
times stated. Cells were then lysed in 1% SDS-lysis buffer. The levels of the indicated proteins were 
determined by immunoblotting.  
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Figure 7 MyD88 Wild Type and Knockout BMDMs.  
BMDMs were stimulated with a) 10µg/ml curdlan b) 200µg/ml depleted zymosan c) 1µg/ml Pam3CSK4 or 
d) 200µg/ml zymosan for the times stated. Cells were then lysed in 1% SDS-lysis buffer. The levels of the 
indicated proteins were determined by immunoblotting. 
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4.3 SYK Inhibition 
It has been shown that Dectin-1 requires SYK for activation of downstream signalling 
pathways and appropriate cytokine responses to fungal ligands. One key study by Rogers 
et al showed that SYK directly interacts with the Dectin-1 tail and that phosphorylated 
SYK is associated with zymosan containing phagosomes. Further, through the use of 
SYK deficient DCs they showed that in the absence of SYK, DCs are unable to produce 
IL-2 and IL-10 in response to zymosan (Rogers, Slack et al. 2005). SYK inhibitors can 
therefore provide a useful tool to analyse Dectin-1 function. 
 
Several small molecules have been described as SYK inhibitors, however in most cases 
selectivity has not been determined. The most commercially available SYK inhibitors are 
SYK inhibitor I, SYK inhibitor II, SYK inhibitor III, SYK inhibitor IV, R406 and 
piceatannol. The structures of these inhibitors and their IC50 for SYK are shown in Table 
4. As there is only limited information on specificity for these compounds, their ability to 
inhibit the activity of a panel of kinases in vitro was determined by the International 
Centre for Kinase Profiling within the DSTT, University of Dundee. The results of this 
screen are shown in figure 8. This shows that SYK inhibitor I at 1µM was able to 
decrease SYK activity to 19%, although unfortunately inhibited other kinases involved in 
cytokine production (such as IKKe) to a much greater extent. SYK inhibitor II at 1µM 
was very selective and inhibited SYK by a significantly greater percentage than almost 
any other kinase tested in the panel. SYK inhibitor III at 1µM was a very poor inhibitor 
of SYK in the screening experiments, actually causing an increase in SYK activity. SYK 
inhibitor IV at 1µM reduced SYK activity to 32%, but inhibited a large number of 
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kinases in the panel to the same extent. R406 at 1µM reduced SYK activity to 5%, but 
notably also inhibited TBK1 and Src to similar levels. Piceatannol at 10µM reduced SYK 
activity to 66%, but reduced the activity of many more kinases by a greater level than 
this. Notable examples of relevant kinases inhibited more than SYK by piceatannol 
include ERK1, IKKe, PKD1, AMPK and IGF1.  
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Table 4 The Structures and SYK IC50 of the 6 Most Commercially Available SYK Inhibitors.  
IC50 values were obtained from the relevant manufacturer. As the IC50s were not all performed and analysed 
at the same time, we must consider that differences in the assay, such as ATP concentration, makes it 
difficult to directly compare values. 
 
SYK inhibitor I SYK inhibitor II
SYK inhibitor III SYK inhibitor IV
Chemical formula C18H15N3O3S
SYK IC50 = 14nM
Chemical formula C14H15F3N6O•2HCl•2H2O
SYK IC50 = 41nM
Chemical formula C9H7NO4
SYK IC50 = 2.5μM
Chemical formula C20H18N6O3•HCl•H2O
SYK IC50 = 10nM
R406 Piceatannol
Chemical formula C14H12O4
SYK IC50 = 3μM
Chemical formula C22H23FN6O5•C6H6O3S
SYK IC50 of 41nM. 
Original Ref: Lai JY (2003) 
Bioorg.Med.Chem Lett. 13:3111
Original Ref: Hisamichi H (2005) 
Bioorg. Med. Chem 13:4936
Original Ref: Wang WY (2006) 
Mol. Pharmacol. 70:1380
Original Ref: Yamamoto N (2003) 
J Pharmacol Exp Ther 306:1174
Original Ref: Braselmann S (2006) 
J Pharmacol Exp Ther 319:998
Original Ref: Oliver JM et al (1994) 
J Bio Chem 269:29697
 79
Figure 8 Kinase Specificity Graphs for SYK Inhibitors I, II, III, IV, R406 and Piceatannol. 
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4.3.1 SYK Inhibitors in A20 Cells 
While in vitro screening can determine inhibitor selectivity, it is also necessary to titrate 
the inhibitor in cells. This is because differences in ATP concentrations between the cell 
and in vitro assays, as well as the ability of the inhibitor to enter the cell, affect the 
concentration required to inhibit SYK in cells. To investigate the effect of SYK inhibitors 
on the activation of SYK in cells, I decided to use a system in which SYK is 
fundamentally required – that is in the signalling downstream of activation of the B-cell 
receptor (Mocsai, Ruland et al. 2010). Using a murine B-cell lymphoma cell line (A20 
cells) I stimulated the B-cell receptor with F(ab’)2 fragment rabbit anti-mouse IgG 
following pre-incubation with the relevant SYK inhibitor. Figure 9 shows that both R406 
and SYK inhibitor II can inhibit ERK1/2 phosphorylation at concentrations above 2µM 
and 10µM respectively, and we can see that neither SYK inhibitor I, SYK inhibitor III 
nor piceatannol can prevent the activation of ERK1/2 at the concentrations used. SYK 
inhibitor IV does cause partial inhibition of ERK1/2 activation. These results are in 
keeping with the kinase specificity screening data, and for my ongoing experiments I 
decided to use only SYK inhibitor II and R406 as these both showed the best SYK 
inhibition in this B cell system. 
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Figure 9 SYK Inhibitors in A20 Cells 
The cells were pre-incubated for 1 hour with the stated concentrations of SYK inhibitor I, SYK inhibitor II, 
SYK inhibitor III, SYK inhibitor IV, R406 or piceatannol. The B-cell receptor was then stimulated for 
30min with F(ab’)2 fragment rabbit anti-mouse IgG. Cells were lysed in triton lysis buffer, protein 
concentration determined, and 20µg of protein denatured with SDS allowing the levels of the indicated 
proteins to be determined by immunoblotting. 
 
 
 
 
 
 
 
 
 
 
 
 
0
-
SYKi I (µM)
F(ab’)2
14 70 14 2.8 0.56 0.1120
+ - + + + + +
P.ERK1/2
T.ERK1/2
0
-
SYKi II (µM)
P.ERK1/2
T.ERK1/2
F(ab’)2
20 20 10 4 0.8 0.160
+ - + + + + +
0
-
SYKi III (µM)
F(ab’)2
4 20 4 0.8 0.16 0.0320
+ - + + + + +
P.ERK1/2
T.ERK1/2
0
-
SYKi IV (µM)
F(ab’)2
10 50 10 0.2 0.4 0.080
+ - + + + + +
P.ERK1/2
T.ERK1/2
P.ERK1/2
T.ERK1/2
0
-
R406 (µM)
F(ab’)2
20 20 10 2 0.4 0.080
+ - + + + + +
P.ERK1/2
T.ERK1/2
0
-
Piceatannol (µM)
F(ab’)2
30 150 30 6 1.2 0.240
+ - + + + + +
 84
One very surprising result was that piceatannol, which is widely used in the literature as a 
SYK inhibitor, did not cause any SYK inhibition in the B cell system. This was 
unexpected, and so to ensure there were no confounding factors within the source of the 
inhibitor I confirmed my findings by using piceatannol from both Calbiochem and Sigma 
(data not shown). Both sources of piceatannol gave identical results. To try and find an 
explanation for this, I reviewed the literature that first described piceatannol as an 
inhibitor of SYK.  
 
Piceatannol is a naturally occurring plant stilbene that was initially shown to inhibit 
purified thymocyte p40 kinase (the catalytic fragment of SYK) in vitro by competition for 
the tyrosine peptide/protein substrate binding site (Geahlen and McLaughlin 1989). 
Further in vitro assays showed that piceatannol was more selective for SYK than the Src 
family kinase Lyn, as measured by autophosphorylation in anti-kinase immune 
complexes and by phosphorylation of a common peptide substrate (angiotensin I) (Oliver, 
Burg et al. 1994). Following this, the effects of piceatannol were studied in RBL-2H3 
cells. Here the authors showed that piceatannol caused a dose dependent inhibition of the 
in vivo phosphorylation of SYK and most other cellular proteins (the doses of piceatannol 
used were from10µg/ml to 50µg/ml). Concentrations of piceatannol that inhibited the 
antigen-stimulated phosphorylation of SYK and multiple other substrates caused a 
general inhibition of receptor mediated metabolic and functional responses in mast cells 
(Oliver, Burg et al. 1994). SYK is known to be activated by collagen stimulation in 
platelets, and Keely et al used piceatannol to clarify the substrates of SYK in this setting. 
Using immune complex kinase assays they showed that pretreatment of platelets with 
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piceatannol at very high concentrations (50µg/ml) inhibited SYK kinase activity, 
measured by autophosphorylation and by the phosphorylation of the exogenous substrate 
tubulin, while not affecting Src kinase activity. However, using piceatannol at lower 
concentrations (10µg/ml) did not significantly inhibit SYK kinase activity, but did inhibit 
the tyrosine phosphorylation of SYK (Keely and Parisle 1996), suggesting that 
piceatannol can also affect other kinases in platelets too. More recently, the antioxidant 
effect of piceatannol has been investigated. Initially, the mechanism by which piceatannol 
is able to scavenge free radicals was investigated using Density Functional Theory (in 
depth account in (Piotrowska, Kucinska et al. 2012). Following this, the antioxidant 
effect of piceatannol in cells was tested, with pretreatment of piceatannol able to 
significantly inhibit the incidence of DNA single strand breaks induced by H2O2 in three 
separate leukemic cell lines (Ovesna, Kozics et al. 2006). This antioxidant effect was also 
present in melanoma B16 cells, which showed significant decreases in reactive species 
generation in cell culture supernatant following piceatannol treatment (Yokozawa and 
Kim 2007). Further, it was shown that piceatannol had a potent anti-melanogenic effect, 
as it was able to decrease melanin content without affecting cell viability (Yokozawa and 
Kim 2007), allowing suggestion that piceatannol may be a potential treatment for 
hyperpigmentation. From these studies, it is clear that piceatannol has a broad spectrum 
of biological activities, although its specificity for SYK has never been directly proven. It 
has been shown that the effect of piceatannol in vitro on SYK is greater than its effect on 
other Src family members, but that does not prove specificity or selectivity for SYK in 
vivo, and does not account for off target effects on other non-Src family kinases. 
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4.3.2 SYK Inhibitors in Wild Type BMDMs  
Using the two most effective SYK inhibitors, SYK inhibitor II and R406, I next 
examined the effect of SYK inhibition on signalling pathways in wild type BMDMs 
following stimulation with zymosan, curdlan, depleted zymosan or LPS. As discussed 
earlier, Dectin-1 is reported to require SYK for the activation of downstream pathways. 
Thus, a SYK inhibitor should block signalling downstream of Dectin-1. The activation of 
the ERK1/2 and p38 pathways by depleted zymosan and curdlan are dependent upon 
Dectin-1 (figure 6), and consistent with an essential role for SYK downstream of Dectin-
1, SYK inhibitor II blocked the activation of both ERK1/2 and p38 by either curdlan or 
depleted zymosan. In addition, SYK inhibitor II also blocked the phosphorylation of 
p105, a substrate of the IKK complex, and TBK1 (Figure 10). 
 
LPS signals via TLR4 and would be expected to be able to activate signalling 
independently of SYK. Consistent with this, SYK inhibitor II did not affect LPS induced 
MAPK activation (figure 10). Zymosan signals via Dectin-1 and TLRs (figures 6 and 7) 
and as such, SYK inhibitor II had a slight effect on ERK1/2 and p38 activation by 
zymosan, whilst the phosphorylation of p105 was slightly reduced (figure 10). This is a 
similar pattern that we see in the Dectin-1 knockout in response to zymosan (figure 6). 
 
The effect of R406 in wild type BMDMs is not as straightforward (figure 11). In response 
to LPS, R406 did not affect the activation of ERK1/2 or p38. In contrast it did reduce the 
phosphorylation of TBK1 on Ser172. Interestingly, TBK1 was one of the kinases 
inhibited by R406 in the in vitro screen.  
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In response to zymosan, R406 reduced the phosphorylation of ERK1/2, p38, p105 and 
TBK1. This would agree with the dual roles of TLR and Dectin-1 in the response to 
zymosan. The effects of R406 on curdlan or depleted zymosan stimulated macrophages 
however were surprising. Unlike SYK inhibitor II, R406 did not completely block 
curdlan or depleted zymosan pathway activation but instead changed its kinetics. The 
presence of R406 causes a significant time delay in activation of ERK1/2, p38, p105 and 
TBK1, i.e. R406 blocks initial phosphorylation of these proteins, but not the 
phosphorylation that occurs at later time points. Similar results were obtained in repeat 
experiments. There is no obvious explanation for this finding, although we must consider 
how R406 maybe metabolized or rendered inactive by the macrophages, or how any off 
target effects of the inhibitor may affect the activation of signalling cascades.  
 
In both LPS and zymosan stimulated BMDMs R406 significantly decreased the 
activation of TBK1, which was not seen with SYK inhibitor II. These findings suggest 
that the inhibition of TBK1 is an off target effect of R406 rather than a consequence of 
SYK inhibition, but in vivo this off target effect on TBK1 may actually be contributing to 
the clinical efficacy seen with R406. The question therefore is does decreased Ser172 
TBK1 phosphorylation have these profound effects on cytokine production? TBK1 is 
known, alongside IKKε, to be essential in regulating the production of type I interferons 
by phosphorylating the transcription factor IRF3 downstream of TLR3 and TLR4 
activation (Hemmi, Takeuchi et al. 2004). 
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 It has been suggested, based on over expression studies, that phosphorylation of TBK1 at 
Ser172 was an autophosphorylation event (Shimada, Kawai et al. 1999). More recently, 
through the use of a specific TBK1 inhibitor, BX795, it has been shown that Ser172 
phosphorylation and activation of overexpressed TBK1 can be blocked by BX795 (Clark, 
Plater et al. 2009). However, BX795 can not suppress the Ser172 phosphorylation and 
activation of  endogenous TBK1 in BMDMs in response to TLR3, TLR4, IL-1α or TNFα 
stimulation (Clark, Plater et al. 2009). This demonstrates that although TBK1 can 
autoactivate in an overexpression system, the activation of the endogenous TBK1 is by an 
upstream activating kinase that is as yet unidentified. It is therefore possible that R406 is 
targeting the activating upstream kinase of TBK1, whatever that maybe.  
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Figure 10 SYK Inhibitor II in Wild Type BMDMs 
The cells were pre-incubated for 1 hour with 4µM SYK inhibitor II. The BMDMs were stimulated with 
10µg/ml curdlan, 200µg/ml depleted zymosan, 200µg/ml zymosan and 100ng/ml LPS as indicated for the 
times stated. Cells were then lysed in 1% SDS-lysis buffer. The levels of the indicated proteins were 
determined by immunoblotting. 
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Figure 11 SYK Inhibitor R406 in Wild Type BMDMs 
The cells were pre-incubated for 1 hour with 10µM R406. The BMDMs were stimulated with  10µg/ml 
curdlan, 200µg/ml depleted zymosan, 200µg/ml zymosan and 100ng/ml LPS as indicated for the times 
stated. Cells were then lysed in 1% SDS-lysis buffer. The levels of the indicated proteins were determined 
by immunoblotting. 
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To asses the effect of SYK inhibitor II and R406 on cytokine expression and secretion I 
pre-incubated wild type BMDMs with either inhibitor and then stimulated with either 
curdlan, depleted zymosan, LPS, Pam3CSK4 or zymosan for 1 hour or 8 hours. As the 
levels of induction are very different between the Dectin-1 only agonists and the TLR 
agonists, I have analyzed the data separately. Looking at the Dectin-1 agonists curdlan or 
depleted zymosan stimulations (Figure 12), it is apparent that SYK inhibitor II is capable 
of significantly reducing the expression and secretion of IL-6, TNFα and IL-12 (p40), 
which is in keeping with the inhibition of MAPK and IKK activation seen by Western 
blotting in the presence of SYK inhibitor II (Figure 10). Interestingly, SYK inhibitor II 
also significantly decreases the expression and secretion of IL-10 (Figure 12). This 
suggests SYK inhibitor II causes a pan cytokine suppression, that is can suppress pro-
inflammatory and anti-inflammatory cytokines equally, and as such, the effect in vivo of 
SYK inhibitor II cannot easily be predicted, and may not be beneficial for anti-
inflammatory actions. The effect of R406 is not as clear, as its effect seems to be 
dependent upon the cytokine involved and the time point observed post stimulation 
(Figure 12). Like SYK inhibitor II, R406 blocked both TNFα mRNA induction and 
secretion in response to depleted zymosan or curdlan. R406 did not significantly affect 
IL-6 secretion, however it did result in a decrease in IL-6 mRNA levels at 8 hours 
following curdlan, but not depleted zymosan, stimulation. R406 did not block the initial 
induction of IL-10 mRNA at 1 hour but did greatly reduce IL-10 mRNA levels at 8 hours. 
Despite this, it did not affect IL-10 secretion in response to curdlan but did cause a small 
reduction in response to depleted zymosan.  
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In response to curdlan, the differences in IL-10 secretion at 8 hours versus mRNA 
expression at 1 and 8 hours may simply be a time delay, with the secretion shown at 8 
hours actually reflecting the increase in expression seen earlier. Another possibility is that 
this increase in cytokine secretion is causing a feedback that may explain why R406 
causes late activation of the MAPK signalling pathways (Figure 11). It would be 
interesting to repeat this experiment over a time course, because if this theory is correct, 
we would expect to see even bigger differences in expression at 4 hours. 
  
Figure 12 Cytokine mRNA Expression and Cytokine Secretion in Response to Curdlan or Depleted 
Zymosan in Wild Type BMDMs +/- SYK Inhibitors.  
BMDMs incubated for 1 hour with inhibitors 4µM SYK inhibitor II or 10µM R406 prior to stimulation for 
1 hour or 8 hours with either 10µg/ml curdlan or 200µg/ml depleted zymosan. Quantitative PCR of mRNA 
has the results normalized to expression of 18s RNA and the fold induction calculated relative to 
unstimulated expression. Error bars show the SEM of 4 independent stimulations (students t-test: NS is not 
significant; * p <0.05; ** p <0.01; *** p <0.001). 
      
 
  
 
 
 
 
 
 
 
 
 
0
5
10
15
20
25
30
35
40
Control Curdlan Depleted Zy
IL
-6
 m
R
N
A
 F
ol
d 
In
du
ct
io
n
1 hour IL-6
0
20
40
60
80
100
120
140
Control Curdlan Depleted Zy
IL
-6
 m
R
N
A
 F
ol
d 
In
du
ct
io
n
8 hours IL-6
a) IL-6
Stimuli only
+ R406
+ SYK Inhibitor II
0
5
10
15
20
25
30
35
Control Curdlan Depleted Zy
IL
-6
 (p
g/
m
l)
8 hours IL-6
mRNA Expression
Cytokine Secretion
NS
*
NS
***
***
***
NS
***
NS
***
NS
***
IL
-6
 m
R
N
A
 F
ol
d 
In
du
ct
io
n
IL
-6
 m
R
N
A
 F
ol
d 
In
du
ct
io
n
IL
-6
 (p
g/
m
l)
 93
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
0
50
100
150
200
250
300
350
400
Control Curdlan Depleted Zy
TN
Fa
 (p
g/
m
l)
8 hours TNFα
0
10
20
30
40
50
60
70
80
Control Curdlan Depleted Zy
TN
Fa
 m
R
N
A
 F
ol
d 
In
du
ct
io
n
1 hour TNFα
0
20
40
60
80
100
120
Control Curdlan Depleted Zy
TN
Fa
 m
R
N
A
 F
ol
d 
In
du
ct
io
n
8 hours TNFα
b) TNFα
Stimuli only
+ R406
+ SYK Inhibitor II
mRNA Expression
Cytokine Secretion
**
**
***
***
***
***
***
***
***
***
***
***
TN
Fa
 (p
g/
m
l)
TN
Fa
 m
R
N
A
 F
ol
d 
In
du
ct
io
n
TN
Fa
 m
R
N
A
 F
ol
d 
In
du
ct
io
n
0
5
10
15
20
25
30
35
40
Control Curdlan Depleted Zy
IL
-1
0 
m
R
N
A
 F
ol
d 
In
du
ct
io
n
1 hour IL-10
0
0.5
1
1.5
2
2.5
3
3.5
4
4.5
5
Control Curdlan Depleted Zy
IL
-1
0 
m
R
N
A
 F
ol
d 
In
du
ct
io
n
8 hours IL-10
c) IL-10
0
5
10
15
20
25
30
35
40
45
50
Control Curdlan Depleted Zy
IL
-1
0 
(p
g/
m
l)
8 hours IL-10
Stimuli only
+ R406
+ SYK Inhibitor II
mRNA Expression
Cytokine Secretion
**
*
NS
***
***
***
***
*** NS
***
**
***
IL
-1
0 
m
R
N
A
 F
ol
d 
In
du
ct
io
n
IL
-1
0 
m
R
N
A
 F
ol
d 
In
du
ct
io
n
IL
-1
0 
(p
g/
m
l)
 94
 
 
0
5
10
15
20
25
30
35
Control Curdlan Depleted Zy
IL
-1
2 
(p
40
) m
R
N
A
 F
ol
d 
In
du
ct
io
n
1 hour IL-12 (p40)
0
20
40
60
80
100
120
140
160
Control Curdlan Depleted Zy
IL
-1
2 
(p
40
) m
R
N
A
 F
ol
d 
In
du
ct
io
n
8 hours IL-12 (p40)
d) IL-12 (p40)
Stimuli only
+ R406
+ SYK Inhibitor II
mRNA Expression
Cytokine Secretion
0
5
10
15
20
25
Control Curdlan Depleted Zy
IL
-1
2 
p4
0 
(p
g/
m
l)
8 hours IL-12 (p40)
***
**
NS
NS
***
***
NS
***
NS
***
*
*
IL
-1
2 
(p
40
) m
R
N
A
 F
ol
d 
In
du
ct
io
n
IL
-1
2 
(p
40
) m
R
N
A
 F
ol
d 
In
du
ct
io
n
IL
-1
2 
p4
0 
(p
g/
m
l)
 95
Next, I investigated the effect of SYK inhibitor II and R406 in response to the TLR 
ligands Pam3CSK4 and LPS, and the TLR and Dectin-1 ligand zymosan (Figure 13). 
SYK inhibitor II is not effective at blocking TNFα or IL-6 expression in response to LPS 
or Pam3CSK4. SYK inhibitor II is more effective at blocking zymosan induced TNFα 
and IL-6 expression, but only at the 8 hour time point, which may be explained by SYK 
inhibitor II effect on the Dectin-1 component of zymosan signalling. Although SYK 
inhibitor II had only mild effects on IL-6 and TNF mRNA, it did strongly suppress their 
secretion in response to LPS, Pam3CSK4 and zymosan. This suggests that SYK inhibitor 
II targets either the translation or secretion of these cytokines rather than their 
transcription. SYK inhibitor II upregulated the expression of IL-10 at the 1 hour time 
point in response to LPS, Pam3CSK4 and zymosan, however, by 8 hours SYK inhibitor 
II repressed IL-10 mRNA and IL-10 secretion levels.  SYK inhibitor II is able to 
significantly inhibit the expression and secretion of IL-12 (p40) at both 1 hour and 8 
hours in response to LPS, Pam3CSK4 and zymosan, whilst its effect on other pro-
inflammatory cytokines studied is limited. This suggests that perhaps IL-12 (p40) 
induction downstream of TLRs is linked to SYK (or another kinase targeted by SYK 
inhibitor II) that is not involved in the induction of the other pro-inflammatory cytokines 
I have measured.  
 
R406 has a huge effect on the expression and secretion of pro-inflammatory cytokines in 
response to either LPS, Pam3CSK4 or zymosan (Figure 13), resulting in an almost 
complete suppression in expression and secretion of TNFα, IL-6 and IL-12 (p40). At 1 
hour, R406 does cause a very modest increase in the expression of IL-10 in Pam3CSK4 
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or zymosan stimulated BMDMs, although by 8 hours R406 has significantly reduced (to 
control levels) the amount of IL-10 expressed, and the level of IL-10 secreted is minimal. 
It therefore seems very unlikely that the suppressive effect of R406 on pro-inflammatory 
cytokines is due to changes in IL-10. When analyzing the cytokine data along side the 
pathway activation Western blots (Figure 11) it becomes apparent that the effect of R406 
is much greater than that expected by the modest effect on MAPK or NFκB signalling. 
Given that R406 has poor selectivity for SYK and yet has a much greater effect on 
cytokine production than SYK inhibitor II, it is likely that much of its effect is due to off 
target activities. 
 
Further consideration needs to be given to the effect of both SYK inhibitors, but 
especially R406, on LPS stimulated BMDMs. As previously discussed, we see that in the 
presence of R406 p38, ERK1/2 and p105 are still fully activated whilst cytokine 
expression and secretion are suppressed. This scenario has been reported in the literature 
previously in the MyD88 or Trif knockout mice, where in response to LPS the MAPK 
pathways are still activated but the cytokine expression is significantly reduced. Looking 
at the kinase specificity screening data we could make suggestions of other kinases whose 
activities are also affected by R406, such as IKK. However, Figure 11 shows that IkBα 
degradation is unchanged in the presence of R406 which suggests that the IKK complex 
activity is unaffected by R406. We must remember that the kinase screening database has 
only looked at a fraction of the kinases at play, and there could be further targets of R406 
that have not yet been discovered. Further, the effect of the inhibitor on a kinase in vitro 
may be different to the effect on that same kinase in vivo, as other effects such as cellular 
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ATP levels, concentrations of substrates and activators present will vary in the cellular 
system when compared to in vitro assays.  
 
 
 
 
 
Figure 13 Cytokine mRNA Expression and Cytokine Secretion in Response to a Variety of Stimuli in 
Wild Type BMDMs +/- SYK Inhibitors.  
BMDMs incubated for 1 hour with inhibitors 4µM SYK inhibitor II or 10µM R406 prior to stimulation for 
1 hour or 8 hours with 100ng/ml LPS, 1µg/ml Pam3CSK4 or 200µg/ml zymosan. Quantitative PCR of 
mRNA has the results normalized to expression of 18s RNA and the fold induction calculated relative to 
unstimulated expression. Error bars show the SEM for 4 independent stimulations. A student’s t-test (2-
sided) was performed on the results; NS is not significant; * p <0.05; ** p <0.01; *** p <0.001. 
0
1000
2000
3000
4000
5000
6000
7000
8000
Control LPS Pam3CSK4 Zymosan
IL
-6
 (p
g/
m
l)
a) IL-6
0
200
400
600
800
1000
1200
Control LPS Pam3CSK4 Zymosan
IL
-6
 m
R
N
A
 F
ol
d 
In
du
ct
io
n
0
20000
40000
60000
80000
100000
120000
140000
160000
Control LPS Pam3CSK4 Zymosan
IL
-6
 m
R
N
A
 F
ol
d 
In
du
ct
io
n
1 hour IL-6
8 hours IL-68 hours IL-6
Stimuli only
+ R406
+ SYK Inhibitor II
mRNA Expression
Cytokine Secretion
NS
NS
NS
**
*
***
NS
**
NS
***
***
*** ***
***
***
**
*
**
IL
-6
 (p
g/
m
l)
IL
-6
 m
R
N
A
 F
ol
d 
In
du
ct
io
n
IL
-6
 m
R
N
A
 F
ol
d 
In
du
ct
io
n
 98
0
10000
20000
30000
40000
50000
60000
Control LPS Pam3CSK4 Zymosan
TN
Fa
 (p
g/
m
l)
8 hours TNFα
b) TNFα
0
100
200
300
400
500
600
700
Control LPS Pam3CSK4 Zymosan
TN
Fa
 m
R
N
A
 F
ol
d 
In
du
ct
io
n
0
200
400
600
800
1000
1200
1400
1600
1800
Control LPS Pam3CSK4 Zymosan
TN
Fa
 m
R
N
A
 F
ol
d 
In
du
ct
io
n
1 hour TNFα
8 hours TNFα
Stimuli only
+ R406
+ SYK Inhibitor II
mRNA Expression
Cytokine Secretion
**
***
**
***
NS
***
***
***
***
***
***
*** ***
***
***
***
***
***
TN
Fa
 (p
g/
m
l)
TN
Fa
 m
R
N
A
 F
ol
d 
In
du
ct
io
n
TN
Fa
 m
R
N
A
 F
ol
d 
In
du
ct
io
n
0
50
100
150
200
250
300
350
400
Control LPS Pam3CSK4 Zymosan
IL
-1
0 
m
R
N
A
 F
ol
d 
In
du
ct
io
n
1 hour IL-10
0
500
1000
1500
2000
2500
Control LPS Pam3CSK4 Zymosan
IL
-1
0 
m
R
N
A
 F
ol
d 
In
du
ct
io
n
8 hours IL-10
c) IL-10
Stimuli only
+ R406
+ SYK Inhibitor II
mRNA Expression
Cytokine Secretion
0
500
1000
1500
2000
2500
Control LPS Pam3CSK4 Zymosan
IL
-1
0 
(p
g/
m
l)
8 hours IL-10
*
NS
***
**
**
NS
**
***
**
**
***
***
***
***
***
**
**
***
IL
-1
0 
m
R
N
A
 F
ol
d 
In
du
ct
io
n
IL
-1
0 
m
R
N
A
 F
ol
d 
In
du
ct
io
n
IL
-1
0 
(p
g/
m
l)
 99
 d) IL-12 (p40)
0
200
400
600
800
1000
1200
1400
1600
Control LPS Pam3CSK4 Zymosan
IL
-1
2 
(p
40
) m
R
N
A
 F
ol
d 
In
du
ct
io
n
1 hour IL-12 (p40)
0
5000
10000
15000
20000
25000
30000
35000
Control LPS Pam3CSK4 Zymosan
IL
-1
2 
(p
40
) m
R
N
A
 F
ol
d 
In
du
ct
io
n
8 hours IL-12 (p40)
Stimuli only
+ R406
+ SYK Inhibitor II
mRNA Expression
Cytokine Secretion
0
200
400
600
800
1000
1200
1400
1600
1800
2000
Control LPS Pam3CSK4 Zymosan
IL
-1
2 
p4
0 
(p
g/
m
l)
8 hours IL-12 (p40)
***
***
*
***
NS
**
**
**
*
*
***
***
***
***
***
***
***
***
IL
-1
2 
(p
40
) m
R
N
A
 F
ol
d 
In
du
ct
io
n
IL
-1
2 
(p
40
) m
R
N
A
 F
ol
d 
In
du
ct
io
n
IL
-1
2 
p4
0 
(p
g/
m
l)
 100
4.4 Dectin-1 Ligands Activate ERK1/2 via an Unidentified 
Kinase 
For most stimuli, Raf-1 activates MEK1/2 which activates ERK1/2 (Kolch 2000). 
However, TLR signalling is unusual in that the pathway involves the serine/threonine 
kinase Tpl2. Before activation, Tpl2 is in an inactive complex with p105 and Abin2. TLR 
signalling activates IKKs which phosphorylates p105, causing it to dissociate from Tpl2 
and allowing p105 proteolysis (Waterfield, Zhang et al. 2003). The activated Tpl2 
activates MEK1/2 which in turn activates ERK1/2 (Das, Cho et al. 2005).It is not clear if 
signalling from Dectin-1 uses Raf-1 or Tpl2. It may be hypothesised that Raf-1 is 
responsible for activating ERK1/2, via MEK1/2, downstream of Dectin-1 as other ITAM 
containing receptors, for example the B-cell receptor, are known to require Raf-1 to 
activate ERK1/2 (Reviewed in (Kolch 2000). However, there is a report that shows that 
SYK is required for Tpl2 activation of ERK1/2 following TNFα stimulation of BMDMs 
(Eliopoulos, Das et al. 2005). As Dectin-1 utilises SYK, it is feasible that Tpl2 maybe the 
kinase responsible for the activation of ERK1/2 via MEK1/2. To investigate the potential 
roles of Raf-1 and Tpl2 downstream of Dectin-1 I initially used the Tpl2 inhibitor 
SHN681 (Hall, Kurdi et al. 2007).  
 
Figure 14 shows that a concentration of 10µM of SHN681 is required to fully inhibit 
signalling from TLR4 (using LPS as an agonist). When zymosan was used as a stimulus 
10µM of SHN681 was able to greatly reduce but not block ERK1/2 activation. Figure 15 
shows that using the Dectin-1 only stimuli depleted zymosan 10µM of SHN681 can again 
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reduce, but not completely block ERK1/2 activation. This suggests that Dectin-1 may 
activate ERK1/2 through both Tpl2 dependent and independent mechanisms. 
 
 
Figure 14 Zymosan and LPS Stimulation of Wild Type BMDMs with Tpl2 Inhibitor SHN681. 
BMDMs were incubated with SHN681 at the stated concentrations for 1 hour prior to stimulation. The 
BMDMs were stimulated with either 200µg/ml zymosan or 100ng/ml LPS. BMDMs were lysed with 1% 
SDS lysis buffer and the levels of the indicated proteins were determined by immunoblotting. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 15 Depleted Zymosan in Wild Type BMDMs +/- the Tpl2 Inhibitor SHN681 
BMDMs were incubated with 10µM SHN681 1 hour prior to stimulation with 200µg/ml depleted zymosan. 
BMDMs were lysed in 1% SDS lysis buffer and the levels of the indicated proteins were determined by 
immunoblotting. 
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To investigate the role of Tpl2 further, I used the small molecule IKKβ inhibitor 
BIX02514 to prevent the phosphorylation of p105 and block the release of active Tpl2 
(Figure 16). With zymosan stimulation BIX02514 gives complete inhibition of IKKβ, as 
shown by the lack of phosphorylation of the IKKβ substrate p105, and the lack of 
degradation of IkappaBα. In the presence of BIX02514 zymosan does not activate 
ERK1/2 (Figure 16a). The Dectin-1 only stimuli curdlan (Figure 16b) and depleted 
zymosan (Figure 16c) show that BIX02514 can block the degradation of IkappaBα and 
phosphorylation of p105, whilst ERK1/2 remains fully activated. In contrast to the results 
with SHN681, this suggests that ERK1/2 is activated by a non-Tpl2 dependent 
mechanism downstream of Dectin-1.  
 
To support the IKKβ inhibitor data, I utilised Abin2 knockout BMDMs. Abin2 forms a 
complex with p105 and Tpl2, and is required for activation of Tpl2. Figure 17a shows 
that in response to the TLR2 ligand Pam3CSK4 the Abin2 knockout BMDMs show 
greatly reduced ERK1/2 activation relative to the wild type BMDMs. Activation of p38 is 
however normal in the Abin2 knockout BMDMs. In response to zymosan, ERK1/2 
activation is decreased when compared to the wild type, but there is still ERK1/2 
phosphorylation (Figure 17b). The Dectin-1 only ligands curdlan (Figure 17c) and 
depleted zymosan (Figure 17d) show fractionally less ERK1/2 phosphorylation in the 
Abin2 knock out BMDMs, but this difference is very marginal. This offers further 
support to the hypothesis that there is an alternative pathway to Tpl2 responsible for the 
activation of ERK1/2 downstream of Dectin-1. 
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Figure 16 Wild Type BMDMs +/- IKKβ Inhibitor BIX02514  
BMDMs were incubated with BIX02514 at a concentration of 10µM for 1 hour prior to stimulation with 
either a) 200µg/ml zymosan b) 10µg/ml curdlan or c) 200µg/ml depleted zymosan. BMDMs were then 
lysed in 1% SDS lysis buffer. The levels of the indicated proteins were determined by immunoblotting. 
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Figure 17 Abin2 Wild Type and Knockout BMDMs. 
BMDMs were stimulated for the stated times with either a) 1µg/ml Pam3CSK4, b) 200µg/ml zymosan,     
c) 10µg/ml curdlan, or d) 200µg/ml depleted zymosan. BMDMs were then lysed in 1% SDS lysis buffer. 
The levels of the indicated proteins were determined by immunoblotting. 
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To clarify the role of Tpl2 in the activation of ERK1/2 downstream of Dectin-1 I isolated 
BMDMs from Tpl2 knock out mice. Figure 18a shows that as expected, in Pam3CSK4 
stimulated Tpl2 knock out BMDMs p105 phosphorylation was apparent but no ERK1/2 
activation was seen. In zymosan stimulated Tpl2 knock out BMDMs I saw no ERK1/2 
activation which suggests that zymosan acts so strongly through TLR2 initially that we 
are unable to see the contribution of the Dectin-1 component of signalling (figure 18b). 
When the Tpl2 knock out BMDMs are stimulated only through Dectin-1 (figure 18 c&d), 
ERK1/2 activation is the same intensity as in the wild type BMDMs. This suggests that 
the activating pathway to ERK1/2 from Dectin-1 is not Tpl2 dependent. Interestingly, the 
Tpl2 inhibitor SHN681 is still able to inhibit the activation of ERK1/2 in the Tpl2 knock 
out BMDMs. It is therefore clear that the kinase responsible for the phosphorylation of 
ERK1/2 in this setting is an unidentified off target effect of SHN681.  
 
The obvious hypothesis is that Raf-1 is the kinase responsible for the activation of 
MEK1/2 and then ERK1/2 downstream of Dectin-1. To investigate this further I 
stimulated wild type BMDMs with the ligand PMA, which is known to activate ERK1/2 
via Raf-1. Figure 19 shows that although ERK1/2 phosphorylation is reduced by the 
addition of SHN681, it is not blocked. This shows that Raf-1 is inhibited by SHN681 to 
some extent, but not fully, and therefore there is likely to be another kinase involved. The 
involvement of Raf-1 however is notoriously difficult to prove, as most of the Raf-1 
inhibitors available do not fully inhibit all isoforms of Raf-1 because, as it is so 
fundamental for cells, Raf-1 employs many feedback loops to both suppress and induce 
its own activation (Hall-Jackson, Goedert et al. 1999). 
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Figure 18 Tpl2 Wild Type and Knockout BMDMs. 
BMDMs were pre-incubated with 10µM SHN681 1 hour prior to stimulation for the stated times with 
either a) 1µg/ml Pam3CSK4 b) 200µg/ml zymosan c) 10µg/ml curdlan d) 200µg/ml depleted zymosan. 
BMDMs were lysed with 1% SDS lysis buffer and levels of the indicated protein determined by 
immunoblotting. 
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Figure 19 PMA Stimulation in Wild Type BMDMs +/- the Tpl2 Inhibitor SHN681 
BMDMs were pre-incubated with 10µM SHN681 1 hour prior to stimulation for the stated times with 
400ng/ml PMA. BMDMs were lysed with 1% SDS lysis buffer and levels of the indicated protein 
determined by immunoblotting. 
 
 
 
 
 
 
 
 
 
4.5 The Role of MSK1/2 
4.5.1 MSK1/2 is required to activate CREB in response to Dectin-1 
ligands 
Looking further downstream of the signalling pathway from Dectin-1 and TLR2, the role 
of MSK1/2 on the macrophages inflammatory response was investigated. MSK1/2 is 
activated by p38 and ERK1/2, and it has previously been shown that MSK1/2 is required 
for induction of IL-10, and hence suppression of pro-inflammatory cytokines, in response 
to LPS (Ananieva, Darragh et al. 2008). I was interested in investigating if MSK1/2 was 
also required for maximal IL-10 production in response to Dectin-1 stimulation.  
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To start, the small molecule p38 inhibitor SB203580 and the MEK inhibitor PD184352 
were used to chemically inhibit MSK1/2 (Figure 20). In the wild type BMDMs, zymosan 
is able to activate MSK1, as judged by the phosphorylation of MSK1 on Thr581, a site 
that is critical for MSK1 activation. However, using the two inhibitors shows that both 
ERK1/2 and p38 are able to phosphorylate MSK1/2 in response to zymosan, and that this 
inhibition of MSK1/2 prevents the phosphorylation of CREB. This suggests the 
possibility that MSK1/2 are the only activators of CREB induced transcription following 
zymosan stimulation.  
 
To confirm these findings, wild type and MSK1/2 knockout BMDMs were stimulated 
with zymosan over a 6 hour time course (Figure 21). As MSK1/2 is activated downstream 
of p38 and ERK1/2 we would not expect to see any difference in the activation of these 
proteins between the wild type and MSK1/2 knockout BMDMs. As predicted, the 
knockouts showed similar levels of ERK1/2, p38 and JNK activation to the wild type. 
However, while wild type BMDMs are able to phosphorylate CREB and the related 
transcription factor ATF1, this did not occur in the MSK1/2 knockout BMDMs. This 
confirms that MSK1/2 is the only activator of CREB induced transcription following 
zymosan stimulation.   
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Figure 20 Zymosan Stimulation in Wild Type 
BMDMs +/- MAPK Inhibitors  
BMDMs were incubated for 1 hour with stated 
inhibitor prior to stimulation with 200µg/ml 
zymosan for either 1 hour or 8 hours. BMDMs were 
then lysed in 1% SDS lysis buffer and the levels of 
indicated proteins were determined by 
immunoblotting. 
 
Figure 21 Zymosan Stimulation in Wild Type and 
MSK1/2 Knockout BMDMs 
BMDMs were stimulated with 200µg/ml zymosan 
for the times stated. The BMDMs were lysed in 1% 
SDS lysis buffer and the levels of indicated proteins 
were determined by immunoblotting. 
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 To determine if the effect of MSK1/2 activation on CREB phosphorylation seen with 
zymosan is only a result of TLR2 signalling, or if Dectin-1 was also involved, I firstly 
examined the effects of the small molecule p38 inhibitor SB203580 and the MEK 
inhibitor PD184352 on curdlan (Figure 22) and depleted zymosan (Figure 23) stimulated 
BMDMs. This showed that chemically inhibiting MSK1/2 with a combination of 
PD184352 and SB203580 was successful, as judged by lack of p581 MSK1 
phosphorylation, and that this lack of MSK1 activation was associated with lack of 
CREB and ATF1 phosphorylation, notably at the 1 hour time point.  
 
To confirm these results, I examined the effects of the Dectin-1 ligands curdlan or 
depleted zymosan on MSK1/2 knockout BMDMs. Figure 24 shows that in the MSK1/2 
knockout BMDMs the response to curdlan resulted in both p38 and ERK1/2 being 
phosphorylated as the wild type, but that CREB was not phosphorylated at all. Depleted 
zymosan stimulation (Figure 25) supports this finding, showing that CREB is not 
activated in the MSK1/2 knock out BMDMs, whilst p38 and ERK1/2 are phosphorylated 
to the same level as the wild type BMDMs. 
  
The conclusion from these experiments is that MSK1/2 is required to activate CREB in 
response to Dectin-1 stimulation.
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Figure 22 Curdlan Stimulation in Wild 
Type BMDM +/- MAPK Inhibitors  
BMDMs were incubated for 1 hour with 
stated inhibitor prior to stimulation with 
10µg/ml curdlan for either 1 hour or 8 
hours. BMDMs were then lysed in 1% 
SDS lysis buffer and levels of indicated 
proteins were determined by 
immunoblotting.   
 
Figure 23 Depleted Zymosan Stimulation in 
Wild Type BMDMs +/- MAPK Inhibitors  
BMDMs were incubated for 1 hour with stated 
inhibitor prior to stimulation with 200µg/ml 
depleted zymosan for either 1 hour or 8 hours. 
BMDMs were then lysed in 1% SDS lysis buffer 
and levels of indicated proteins were determined 
by immunoblotting 
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Figure 24 Curdlan Stimulation in Wild 
Type and MSK1/2 Knockout BMDMs 
BMDMs were stimulated with 10µg/ml 
curdlan for the times stated. The BMDMs 
were lysed in 1% SDS lysis buffer and 
levels of indicated proteins were determined 
by immunoblotting 
 
 Figure 25 Depleted Zymosan Stimulation in 
Wild Type and MSK1/2 Knockout BMDMs 
BMDMs were stimulated with 200µg/ml 
depleted zymosan for the times stated. The 
BMDMs were lysed in 1% SDS lysis buffer 
and levels of indicated proteins were 
determined by immunoblotting 
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4.5.2 Effect of MSK1/2 on Cytokine Production 
It has previously shown that in response to LPS, MSK1/2 knockout BMDMs show a 
significant increase in the pro-inflammatory cytokines TNFα, IL-6 and IL-12, and that 
this was directly a result of decreased expression and secretion of IL-10. It was also 
shown that in response to LPS, the lack of MSK1/2 prevents the activation of CREB and 
ATF1 which would, in normal circumstances, induce DUSP1, a MAPK phosphatase 
which inactivates p38 and JNK, and increase IL-10 expression (Ananieva, Darragh et al. 
2008).  
 
To assess the effect of the absence of MSK1/2 on the production of cytokines in response 
to Dectin-1 ligands, I firstly used a combination of the p38 inhibitor SB203580, and the 
MEK inhibitor PD184352 to chemically block MSK1/2.  Figure 26 shows that following 
1 hour of stimulation with either zymosan, curdlan or depleted zymosan the levels of IL-
10 mRNA were upregulated. Pretreatment of BMDMs with PD184352 resulted in a 
significant increase in IL-10 mRNA levels in response to zymosan and depleted zymosan. 
SB203580 had little effect on its own, although a combination of SB203580 and 
PD184352 resulted in an inhibition of IL-10 mRNA levels relative to PD184352 alone. 
At 8 hours, in response to zymosan both SB203580 and PD184352 inhibit IL-10 
expression and secretion, but the combination of the two inhibitors is able to suppress IL-
10 expression and secretion to a much greater extent than either inhibitor individually. In 
response to the Dectin-1 ligand curdlan at 8 hours SB203580 was able to suppress IL-10 
expression and secretion, however PD184352 actually caused greater IL-10 expression 
than the non-inhibitor treated BMDMs. At 8 hours, depleted zymosan showed the same 
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trends as curdlan, but the differences in expression levels were not significant. The 
unexpected effects of PD184352 were not due to a failure of the inhibitor, as the 
combination of SB203580 and PD184352 were able to successfully inhibit nur77, a 
known target gene of MSK1/2 (Figure 27). 
 
Figure 26 a) and b) IL-10 mRNA Expression and c) IL-10 Secretion in Response to Dectin-1 Ligands 
in Wild Type BMDMs +/- MAPK Inhibitors. BMDMs incubated for 1 hour with inhibitors prior to 
stimulation for either 1 hour or 8 hours with either 200µg/ml zymosan, 10µg/ml curdlan or 200µg/ml 
depleted zymosan. Quantitative PCR of mRNA, with results normalised to expression of 18s RNA and fold 
induction calculated relative to unstimulated expression. Error bars show the SEM of 4 independent 
stimulations. A student’s t-test (2-sided) was performed on the results; NS is not significant; * p <0.05;  
** p <0.01; *** p <0.001. 
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Figure 27 Nur77 mRNA Expression in Response to Dectin-1 Ligands in Wild Type BMDMs +/- 
MAPK Inhibitors. BMDMs incubated for 1 hour with inhibitors prior to stimulation for 1 hour with either 
200µg/ml zymosan or 10µg/ml curdlan. Quantitative PCR of mRNA, with results normalised to expression 
of 18s RNA and fold induction calculated relative to unstimulated expression. Error bars show the SEM of 
4 independent stimulations. A student’s t-test (2-sided) was performed on the results; NS is not significant; 
* p <0.05; ** p <0.01; *** p <0.001. 
 
 
 
 
 
 
 
 
 
 
 
 
0
500
1000
1500
2000
2500
3000
IL
-1
0 
(p
g/
m
l)
0
5
10
15
20
25
30
IL
-1
0 
(p
g/
m
l)
0
5
10
15
20
25
IL
-1
0 
(p
g/
m
l)
c) Cytokine Secretion IL-10 at 8 hours
Zymosan
Zymosan
- +
-
-
-
-
+ + +
+ +
+PD184352
SB203580
+-
-
Curdlan
Curdlan
- +
-
-
-
-
+ + +
+ +
+PD184352
SB203580
+-
-
Depleted Zy
Depleted Zy
- +
-
-
-
-
+ + +
+ +
+PD184352
SB203580
+-
-
***
NS
******
***
***
***
**
*
IL
-1
0 
(p
g/
m
l)
IL
-1
0 
(p
g/
m
l)
IL
-1
0 
(p
g/
m
l)
0
200
400
600
800
1000
1200
1400
N
ur
77
 m
R
N
A
 F
ol
d 
In
du
ct
io
n
0
10
20
30
40
50
60
N
ur
77
 m
R
N
A
 F
ol
d 
In
du
ct
io
n
Curdlan - +
-
-
-
-
+ + +
+ +
+PD184352
SB203580
+-
-
Curdlan
Zymosan - +
-
-
-
-
+ + +
+ +
+PD184352
SB203580
+-
-
Zymosan
NS
NS
**
NS
NS
**
N
ur
77
 m
R
N
A
 F
ol
d 
In
du
ct
io
n
N
ur
77
 m
R
N
A
 F
ol
d 
In
du
ct
io
n
 116
The use of MAPK inhibitors to chemically prevent the activation of MSK1/2 shows that 
although the IL-10 expressed and secreted in response to Dectin-1 ligands is less in the 
dual inhibited BMDMS, it is not reduced to the same extent as previously reported with 
LPS stimuli (Ananieva, Darragh et al. 2008). To further investigate the requirement of 
MSK1/2, I examined the IL-10 response to Dectin-1 ligands in MSK1/2 knockout 
BMDMs (Figure 28). This shows that in response to zymosan, curdlan and depleted 
zymosan, the MSK1/2 deficient BMDMs both express less IL-10 mRNA and secrete 
significantly less IL-10 than the wild type BMDMs. Together, these results together 
would suggest that MSK1/2 activity is required for maximal IL-10 transcription, but that 
ERK1/2 is able to repress IL-10 transcription via a second MSK1/2 independent pathway. 
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Figure 28 a) IL-10 mRNA Expression and b) IL-10 Secretion in Response to Dectin-1 Ligands in 
MSK1/2 Wild Type and Knockout BMDMs. BMDMs stimulated for stated times with either 200µg/ml 
zymosan, 10µg/ml curdlan or 200µg/ml depleted zymosan. a) Quantitative PCR of mRNA, with results 
normalised to expression of 18s RNA and fold induction calculated relative to wild type expression at 0h. 
Error bars show the SEM of 4 independent stimulations. A student’s t-test (2-sided) was performed on the 
results; NS is not significant; * p <0.05; ** p <0.01; *** p <0.001. 
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IL-10 is known to be a potent anti-inflammatory cytokine, able to limit TNFα, IL-6 and 
IL-12 production following LPS stimulation of BMDMs (Ananieva, Darragh et al. 2008). 
It could therefore be expected that as Dectin-1 stimulated MSK1/2 deficient or inhibited 
BMDMs produce less IL-10, they would produce more pro-inflammatory cytokines. 
Figure 29 shows that zymosan stimulated BMDMs decrease the expression of IL-6 and 
TNFα when treated with the combination of SB203580 and PD184352. Curdlan and 
depleted zymosan show no difference in IL-6 mRNA expression in response to 
SB203580 alone, whilst with PD184352 treatment alone we see a rise in IL-6 
transcription, but a non significant trend towards decreasing TNFα transcription. In 
response to curdlan or depleted zymosan, the combination of SB203580 and PD184352 
together makes no significant difference to the level of IL-6 mRNA expression, however, 
in response to curdlan does produce a decrease in the levels of TNFα mRNA (Figure 29). 
The secretion profiles are more straight forward (Figure 30). In zymosan, curdlan or 
depleted zymosan stimulated BMDMs, pretreatment with either SB203580 or PD184352 
alone causes a significant decrease in secreted TNFα and the combination of both 
SB203580 and PD184352 together reduces TNFα secretion to almost nothing. This is 
consistent with the known roles that p38 and ERK1/2 play in regulating TNFα translation 
and secretion (Kotlyarov, Neininger et al. 1999; Rousseau, Papoutsopopulou et al. 2008). 
In zymosan stimulated BMDMs, either SB203580 or PD184352 alone cause a decrease in 
the secreted levels of IL-6, but together they have a more profound effect. In curdlan 
stimulated BMDMs, neither SB203580 nor PD184352 alone had any effect at all, but in 
combination caused a significant reduction in the secreted levels of IL-6. The depleted 
zymosan treated BMDMs showed a slight decrease in IL-6 secretion in response to 
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SB203580 alone, but in combination with PD184352 had a more profound effect (Figure 
30).  
 
 
 Figure 29 Cytokine mRNA Expression in Response to Dectin-1 Ligands in Wild Type BMDMs +/- 
MAPK Inhibitors. BMDMs incubated for 1 hour with inhibitors prior to stimulation for 8 hours with 
either 200µg/ml zymosan, 10µg/ml curdlan or 200µg/ml depleted zymosan. Quantitative PCR of mRNA, 
with results normalised to expression of 18s RNA and fold induction calculated relative to unstimulated 
expression. Error bars show the SEM of 4 independent stimulations. A student’s t-test (2-sided) was 
performed on the results; NS is not significant; * p <0.05; ** p <0.01; *** p <0.001. 
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Figure 30 Cytokine Secretion in Response to Dectin-1 Ligands in Wild Type BMDMs +/- MAPK 
Inhibitors. BMDMs incubated for 1 hour with inhibitors prior to stimulation for 8 hours with either 
200µg/ml zymosan, 10µg/ml curdlan or 200µg/ml depleted zymosan. Error bars show the SEM of 4 
independent stimulations. A student’s t-test (2-sided) was performed on the results; NS is not significant;   
* p <0.05; ** p <0.01; *** p <0.001. 
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To further study the effect of MSK1/2 deficiency on pro-inflammatory cytokine 
production, I stimulated wild type and MSK1/2 knockout BMDMs with either zymosan, 
curdlan or depleted zymosan (Figure 31 and Figure 32). Although in the MSK1/2 
knockout BMDMs I have shown that less IL-10 is secreted than the wild type in response 
to Dectin-1 ligands, Figure 31 shows that in the MSK1/2 knockout BMDMs there is a 
trend towards increased expression of IL-6 and TNFα mRNA in the knockouts, notably 
at the 4 to 8 hour time points, although this only reached statistical significance in the 
curdlan stimulated BMDMs. Figure 32 shows that there is no difference between the wild 
type or MSK1/2 knockout BMDMs in the secreted levels of IL-6 in response to either 
zymosan, curdlan or depleted zymosan. There is a marginal decrease in the levels of 
TNFα secreted by the MSK1/2 knockout compared to wild type in response to all 3 
stimuli. Overall, this would suggest that IL-10 is much less effective at repressing the 
effects of Dectin-1 stimulated pro-inflammatory cytokines than it is for TLR induced 
cytokine production.  
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Figure 31 Cytokine mRNA Expression in Response to Dectin-1 Ligands in MSK1/2 Wild Type and 
Knockout BMDMs. BMDMs stimulated for stated times with either 200µg/ml zymosan, 10µg/ml curdlan 
or 200µg/ml depleted zymosan. a) Quantitative PCR of mRNA, with results normalised to expression of 
18s RNA and fold induction calculated relative to wild type expression at 0h. Error bars show the SEM of 4 
independent stimulations. A student’s t-test (2-sided) was performed on the results; NS is not significant;   
* p <0.05; ** p <0.01; *** p <0.001. 
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Figure 32 Cytokine Secretion in Response to Dectin-1 Ligands in MSK1/2 Wild Type and Knockout 
BMDMs. BMDMs stimulated for stated times with either 200µg/ml zymosan, 10µg/ml curdlan or 
200µg/ml depleted zymosan. Error bars show the SEM of 4 independent stimulations. A student’s t-test (2-
sided) was performed on the results; NS is not significant; * p <0.05; ** p <0.01; *** p <0.001. 
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4.5.3 MSK1/2 and CREB 
It has been shown that in response to LPS MSK1/2 regulate IL-10 transcription in part 
through the phosphorylation of CREB. It has been shown that CREB binds to the IL-10 
promoter and that CREB phosphorylation at Ser133 is required for maximal IL-10 
transcription (Ananieva, Darragh et al. 2008). It is therefore possible that the effects of 
MSK1/2 knockout we observe are due to the absence of CREB phosphorylation, as figure 
21 has shown that the transcription factors CREB and ATF1 are not activated in the 
absence of MSK1/2.  
 
This was investigated further using BMDMs derived from CREB Serine133 knock-in 
mice. Total knockout of CREB in mice is embryonically lethal, and as such the best 
option for our study is the mutation of serine 133, which allows study of MSK1/2 
function while the serine 133 independent functions of CREB remain unaffected. Figure 
33 shows a zymosan time course in CREB wild type and Serine133 knock-in BMDMs. I 
show that the CREB knock-in BMDMs do express and secrete marginally less IL-10 and 
slightly more TNFα than the wild type BMDMs, although the differences between wild 
type and CREB knock-in BMDMs are not as drastic as those seen between wild type and 
MSK1/2 knockout BMDMs. Further, these results are not straight forward as the knock-
ins unexpectedly express and secrete less IL-6 than the wild types. 
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Figure 33 a) Cytokine mRNA Expression and b) Cytokine Secretion in Response to Zymosan in CREB 
Wild Type and Knock-in BMDMs. BMDMs stimulated for stated times with 200µg/ml zymosan. a) 
Quantitative PCR of mRNA, with results normalised to expression of 18s RNA and fold induction calculated 
relative to wild type expression at 0h. Error bars show the SEM of 4 independent stimulations. A student’s t-test 
(2-sided) was performed on the results; NS is not significant; * p <0.05; ** p <0.01; *** p <0.001. 
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To try and clarify the involvement of CREB in the MSK1/2 knockout cytokine profile we 
used a combination of wild type, MSK1/2 knock out, CREB knock-in and 
MSK1/2/CREB triple mice. Figure 34 shows a zymosan time course in all four 
genotypes, and we see that the mRNA for the pro-inflammatory cytokines TNFα and IL-
12 (p40) are, at the later time, points more highly expressed in the MSK1/2 knockout and 
the MSK1/2 KO/CREB KI triple than in the single CREB knock-in or wild type. This 
maybe in part explained by the finding that, at all but 1 time point, the MSK1/2 knockout 
and the triple knockout genotypes express less IL-10 that the CREB knock-in, although 
the CREB knock-in does still show a significant reduction in expression of IL-10 when 
compared to the wild type. One possible explanation for these findings is that MSK1/2 is 
affecting another transcription factor other than CREB, for example ATF1, which is 
having an additional affect that that of just CREB alone.   
 
Again though, we see that the CREB knock-in expresses significantly less IL-6 than the 
wild type, and the MSK1/2 knockout and triple knock out genotypes both produce the 
same or slightly more IL-6 than the wild type. While a cre site has been reported in the 
IL-6 promoter, it is not clear why the CREB Ser133A knock-in would have a greater 
effect than the MSK1/2 knockout.  
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Figure 34 Cytokine mRNA Expression in Response to Zymosan in WT, CREB KI, MSK1/2 KO and 
MSK1/2 KO/CREB KI BMDMs. BMDMs stimulated for stated times with 200µg/ml zymosan. 
Quantitative PCR of mRNA, with results normalised to expression of 18s RNA and fold induction 
calculated relative to wild type expression at 0h. Error bars show the SEM of 4 independent stimulations. A 
student’s t-test (2-sided) was performed on the results; NS is not significant; * p <0.05; ** p <0.01;  
*** p <0.001. 
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4.5.4 MSK1/2 and IL-10 
IL-10 is an important anti-inflammatory cytokine that is known to suppress TLR induced 
TNFα, IL-6 and IL-12 production in macrophages. As I have shown that MSK1/2 
regulates Dectin-1 induced IL-10 production, I looked to see if the effect of MSK1/2 
knockout on pro-inflammatory cytokines could be explained by changes in IL-10. To do 
this, I used BMDMs from IL-10 knockout and IL-10/MSK1/2 triple knockout mice 
(Figure 35 and 36). These experiments show that in response to LPS the IL-10 knockout 
BMDMs expressed significantly more IL-6, TNFα, IL-12 (p40) and IL-1β than the wild 
type BMDMs, whilst the MSK1/2 knockout BMDMs expressed these pro-inflammatory 
cytokines at a level less than the IL-10 knockout alone, but more than the wild type 
BMDMs. The IL-10/MSK1/2 triple knockout BMDMs expressed these pro-inflammatory 
cytokines at a level similar to that of the IL-10 knockout alone. As LPS signals through 
TLR4, you may expect the TLR2 agonist Pam3CSK4 to show a similar cytokine 
expression profile. In fact, there appears to be very little difference in the response of IL-
6 between genotypes, whilst IL-12 (p40) shows a slight increase in expression and 
secretion in all three knockout genotypes over the wild type. TNFα appears to be affected 
more by the MSK1/2 knockout than the IL-10, as the single IL-10 knockout BMDMs 
show TNFα expression at a level identical to that of the wild type, whilst the MSK1/2 
knockout up regulates TNFα expression compared to the wild type. The IL10/MSK1/2 
triple knockout shows a trend towards upregulating TNFα expression, but did not reach 
statistical significance. 
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The Dectin-1 and TLR2 agonist zymosan shows a similar pattern of cytokine changes as 
LPS, but whilst the IL-10 knockout has a big effect on LPS induced IL-6 and TNFα 
secretion, it only has a minor effect when zymosan is used. Zymosan does cause an 
increase in the expression TNFα, IL-12 (p40) and IL-6 in the IL-10 knockout and the IL-
10/MSK1/2 triple knockout when compared to wild type, whilst the level of induction in 
the MSK1/2 knockout is greater than wild type, but significantly less than that of the IL-
10 knockout genotypes. This supports the hypothesis that the increased levels of pro-
inflammatory cytokines seen in response to zymosan in the MSK1/2 knockout BMDMs 
are likely to be caused by the decrease in IL-10.  The fact that the MSK1/2 knockout 
BMDMs have a reduced level of IL-10 expression and secretion, opposed to a complete 
absence of IL-10, also explains why when I used the IL-10 knockout BMDMs the level 
of pro-inflammatory cytokines increase further – as these mice do have a complete 
absence of all IL-10.  
 
 130
Figure 35 Cytokine mRNA Expression in WT, IL-10 KO, MSK1/2 KO and MSK1/2/ IL-10 Triple 
KO BMDMs. BMDMs stimulated for 8 hours with either 10µg/ml curdlan, 200µg/ml depleted zymosan, 
100ng/ml LPS, 1µg/ml Pam3CSK4 or 200µg/ml zymosan. Quantitative PCR of mRNA, with results 
normalised to expression of 18s RNA and fold induction calculated relative to wild type expression at 0h. 
Error bars show the SEM of 4 independent stimulations. A student’s t-test (2-sided) was performed on the 
results; NS is not significant; * p <0.05; ** p <0.01; *** p <0.001. 
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Figure 36 Cytokine Secretion in WT, IL-10 KO, MSK1/2 KO and MSK1/2/ IL-10 Triple KO 
BMDMs. BMDMs stimulated for 16 hours with either 10µg/ml curdlan, 200µg/ml depleted zymosan, 
100ng/ml LPS, 1µg/ml Pam3CSK4 or 200µg/ml zymosan. Error bars show the SD of 4 independent 
stimulations. A student’s t-test (2-sided) was performed on the results; NS is not significant; * p <0.05;     
** p <0.01; *** p <0.001. 
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4.6 The Action of IL-10 in Fungal Stimulation of BMDMs 
In the MSK1/2 knock out BMDMs, in response to LPS, it has been previously shown that 
there is a large increase in the pro-inflammatory cytokines TNFα, IL-6 and IL-12 as a 
direct result of decreased IL-10 expression and secretion (Ananieva, Darragh et al. 2008). 
As shown in the previous section, MSK1/2 knockout also results in a decrease in IL-10 
secretion in response to zymosan. Despite this, MSK1/2 knockout did not result in big 
increases in zymosan induced TNFα, IL-6 or IL-12 (p40) production. This is in contrast 
to the LPS results and suggests that IL-10 maybe less able to repress zymosan (or Dectin-
1) induced cytokine production relative to LPS/TLR activated BMDMs. In line with this, 
I showed in figure 36 that while zymosan induces more IL-10 secretion than LPS, the IL-
10 knockout had little effect on TNFα or IL-6 production in response to zymosan. To 
investigate this further I stimulated wild type BMDMs with zymosan or LPS and added 
exogenous IL-10 (Figure 37). This showed that large amounts of exogenous IL-10 
completely suppressed LPS induced TNFα, IL-6 and IL-12 (p40) expression and 
secretion, however only very modestly suppressed zymosan induced TNFα, IL-6 and IL-
12 (p40) expression and secretion.  
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Figure 37 a) Cytokine mRNA Expression and b) Cytokine Secretion in Response to Zymosan and 
LPS in +/- IL-10 in Wild Type BMDMs. BMDMs stimulation for 6 hours with 200µg/ml zymosan, 
100ng/ml LPS and 100ng/ml exogenous IL-10 as indicated a) Quantitative PCR of mRNA, with results 
normalised to expression of 18s RNA and fold induction calculated relative to unstimulated expression. 
Error bars show the SEM of 4 independent stimulations. A student’s t-test (2-sided) was performed on the 
results; NS is not significant; * p <0.05; ** p <0.01; *** p <0.001. 
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4.6.1 IL-10 and STAT Activation 
IL-10 exerts its anti-inflammatory effects by inducing the Janus Kinase-STAT3 
pathways. Within this signalling pathway, STAT3 plays a crucial role, as without STAT3 
IL-10 can not effectively suppress pro-inflammatory cytokine expression (Williams, 
Bradley et al. 2004). As zymosan induced a high level of IL-10 secretion, but this was 
unable to repress pro-inflammatory cytokines, I examined the phosphorylation of STAT3 
on tyrosine705 as this is the site phosphorylated by JAK1/Tyk2 in response to IL-10.  
 
Figure 38 shows that I achieve much greater STAT3 (tyrosine705) phosphorylation in 
response to zymosan than to LPS, which is consistent with the higher IL-10 secretion by 
zymosan (Figure 36). Additionally, I see that STAT1 (tyrosine701) and particularly 
STAT5 (tyrosine694) are significantly more activated in response to zymosan than LPS. 
Unfortunately I was unable to assess STAT2 and STAT6, as no adequate antibody was 
available. As other cytokines, in addition to IL-10, can induce STAT3 phosphorylation, it 
was important to determine if zymosan induced STAT3 phosphorylation via an IL-10 
dependent or independent mechanism.  
 
Figure 39 shows that zymosan stimulation in the IL-10 knockout BMDMs does not cause 
STAT3 (tyrosine 705) phosphorylation. In line with the reduced IL-10 production in 
MSK1/2 knockout BMDMs, the MSK1/2 deficient BMDMs showed less zymosan 
induced STAT3 phosphorylation than was seen in the wild type (Figure 40). 
Interestingly, STAT1 and STAT5 are still activated in the IL-10 knockouts, though to a 
lesser extent than the wild types. 
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To show that the IL-10 knockout BMDMs are still capable of IL-10 induced tyrosine705 
STAT3 phosphorylation, I stimulated them with exogenous IL-10. Figure 41 shows that 
IL-10 knockout BMDMs are able to achieve the same STAT3 (tyrosine705) 
phosphorylation in response to exogenous IL-10 that wild type BMDMs do. 
 
In summary, zymosan induced IL-10 does not repress TNFα or IL-6 effectively. This is 
not due to a failure of IL-10 to stimulate BMDMs in the presence of zymosan as STAT3 
phosphorylation still occurs.  
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Figure 38 STAT Activation in Wild Type BMDMs. 
BMDMs were stimulated with 200µg/ml zymosan or 100ng/ml LPS as indicated, and incubated for the 
stated times. Cells were lysed in 1% SDS lysis buffer and levels of the indicated proteins determined by 
immunoblotting. 
 
 
 
 
 
 
 
 
 
Figure 39 STAT Activation in Wild Type and IL-10 Knockout BMDMs.  
BMDMs were stimulated with 200µg/ml zymosan and incubated for the stated times. Cells were lysed in 
1% SDS lysis buffer and levels of the indicated proteins determined by immunoblotting. 
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Figure 40 Zymosan Stimulation in Wild Type and MSK1/2 Knockout BMDMs 
BMDMs were stimulated with 200µg/ml zymosan for the times stated. The BMDMs were lysed in 1% SDS 
lysis buffer and the levels of indicated proteins were determined by immunoblotting. 
 
 
 
 
 
 
 
 
 
 
 
Figure 41 IL-10 Stimulation of Wild Type and IL-10 Knockout BMDMs. 
BMDMs were stimulated with 100ng/ml exogenous IL-10 as indicated, and incubated for the stated times. 
Cells were lysed in 1% SDS lysis buffer and levels of the indicated proteins determined by 
immunoblotting. 
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4.6.2 Phagocytosis and IL-10 
One obvious difference between stimulations with zymosan and LPS is that zymosan is 
phagocytosed whilst LPS is not. To examine whether phagocytosis can explain the 
difference in response to IL-10 produced between zymosan and LPS I used latex beads to 
be phagocytosed whilst co-stimulating with LPS. Figure 42 shows that the addition of 
latex beads does not change the level of expression of IL-10 in response to LPS. A 
combination of latex beads and LPS does reduce the expression of the pro-inflammatory 
cytokines IL-6, IL-12 p40 and IL-1β relative to LPS alone. LPS in combination with latex 
beads causes a small increase in expression of TNFα, so it appears phagocytosis 
contributes to significantly further stimulating TNFα induction, although not to the same 
level as zymosan stimulation. Phagocytosis alone without PRR stimulation does not 
appear to induce any cytokine expression.  
 
To investigate whether phagocytosis is the reason why high levels of IL-10 can not 
repress pro-inflammatory cytokines with zymosan stimulation, we added exogenous IL-
10 to the LPS and latex bead co-stimulation. Figure 43 shows that while the addition of 
beads decreased the ability of LPS to induce IL-6 and IL-12 p40, the addition of 
exogenous IL-10 was able to repress this further. IL-1β expression however is not 
decreased with the addition of IL-10, as it also is not with zymosan stimulation. This 
suggests that it is phagocytosis that prevents the repressive action of IL-10 in IL-1β 
expression. TNFα expression is only marginally decreased by the addition of IL-10 to the 
LPS and bead co-stimulated samples, which suggests that phagocytosis maybe in part 
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responsible for the reduced efficacy of IL-10 in suppressing TNFα in zymosan stimulated 
BMDMs.  
 
 
Figure 42 Cytokine mRNA Expression in Response to Zymosan, LPS and Beads in Wild Type 
BMDMs. BMDMs stimulation for 6 hours with 200µg/ml zymosan, 100ng/ml LPS and 20µl 0.8micron 
latex beads as indicated. Quantitative PCR of mRNA, with results normalised to expression of 18s RNA 
and fold induction calculated relative to unstimulated expression. Error bars show the SEM of 4 
independent stimulations. A student’s t-test (2-sided) was performed on the results; NS is not significant;  
* p <0.05; ** p <0.01; *** p <0.001. 
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Figure 43 Cytokine mRNA Expression in Response to Zymosan, LPS and Beads +/- IL-10 in Wild 
Type BMDMs. BMDMs stimulation for 6 hours with 200µg/ml zymosan, 100ng/ml LPS, 20µl 0.8micron 
latex beads and 100ng/ml IL-10 as indicated. Quantitative PCR of mRNA, with results normalised to 
expression of 18s RNA and fold induction calculated relative to unstimulated expression. Error bars show 
the SEM of 4 independent stimulations. A student’s t-test (2-sided) was performed on the results; NS is not 
significant; * p <0.05; ** p <0.01; *** p <0.001. 
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4.7 Differences between LPS and Zymosan Stimulations  
As I have shown, the BMDMs cytokine profile in response to fungal ligands is similar to 
that of LPS but with several important differences. The first is that, with the exception of 
TNFα, we see significantly less expression and secretion of the pro-inflammatory 
cytokines IL-6 and IL-12 (p40); secondly we see much greater induction and secretion of 
IL-10 in response to fungal ligands, but IL-10 does not seem to repress inflammatory 
cytokines as it does in LPS stimulated BMDMs. I therefore decided to search for a 
possible mediator downstream of IL-10 that regulates pro-inflammatory cytokine 
expression that is different between zymosan and LPS stimulations.  
 
4.7.1 Growth Factor Independent 1  
One putative candidate is Growth Factor Independent 1 (Gfi1), a zinc finger protein that 
functions as a transcriptional repressor. Gfi1 is differentially expressed in haematopoietic 
stem cells, and plays a large role in B and T cell development (Kazanjian, Gross et al. 
2006). Studies in Gfi1 deficient mice show that they are severely neutropenic and 
accumulate immature monocytes in peripheral blood and bone marrow as they are unable 
to differentiate into granulocytes, but can differentiate into macrophages (Karsunky, Zeng 
et al. 2002). Gfi1 deficient macrophages over produce pro-inflammatory cytokines in 
response to LPS and Gfi1 deficient mice are highly susceptible to LPS induced septic 
shock (Karsunky, Zeng et al. 2002). It has been shown that macrophages up regulate Gfi1 
as a directly as a consequence of TLR4 signalling, and not as a consequence of TLR4 
induced inflammatory cytokine production (Moroy, Zeng et al. 2008). The mechanism 
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for the induction of Gfi1 is unclear; however there is evidence that once the Gfi1 gene is 
induced and Gfi1 protein is made it forms a complex in the nucleus with the p65 subunit 
of NF-κB (Sharif-Askari, Vassen et al. 2010). The hypothesis is that this binding prevents 
p65 binding to NF-κB target gene promoters and as such limits the production of pro-
inflammatory cytokines, although this has yet to be proven. It has also been suggested 
that Gfi1 is able to influence IL-10 signalling by interacting with the STAT3 inhibitor 
PIAS3 (protein inhibitor of activated STAT). The role of PIAS3 is to bind to activated, 
phosphorylated STAT3 dimers and block their DNA binding ability (Chung, Liao et al. 
1997). It has been shown that Gfi1 is able to interact with PIAS3, resulting in a reduction 
of the inhibitory effect of PIAS3 on STAT3 activity, and as such Gfi1 could be seen to 
act as an enhancer of signals transduced by STAT3 (Rodel, Tavassoli et al. 2000).  
 
Gfi1 mRNA was found to be induced by LPS but not zymosan (Figure 44). This 
upregulation required an increase in transcription, as primary transcript levels were also 
increased. I did attempt immunoblotting LPS and zymosan treated BMDM samples for 
Gfi1, but could not find an antibody that worked. 
 
To see if the increase in Gfi1 was due directly to LPS stimulation or indirectly from 
another protein that was first increased by LPS we performed an LPS time course with 
and without cycloheximide to block protein synthesis (Figure 45). This suggests that Gfi1 
expression is activated by a secondary protein downstream of LPS and not directly by 
LPS signalling.  
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As discussed earlier, IL-10 is one protein that is induced by LPS stimulation and can 
feedback to affect the induction of gene transcription. The level of LPS induced Gfi1 
expression was decreased by the addition of exogenous IL-10, shown in Figure 46. This 
suggests that either IL-10 signalling in some way might cause a decrease in Gfi1 levels 
either directly, or a consequence of the down regulation of pro-inflammatory cytokines.   
 
 
 
 
 
 
Figure 44 Gfi1 mRNA Expression in Response to LPS and Zymosan in Wild Type BMDMs. BMDMs 
stimulation with 200µg/ml zymosan or 100ng/ml LPS for the stated times. Quantitative PCR of mRNA, 
with results normalised to expression of 18s RNA and fold induction calculated relative to unstimulated 
expression. Error bars show the SEM of 4 independent stimulations. A student’s t-test (2-sided) was 
performed on the results; NS is not significant; * p <0.05; ** p <0.01; *** p <0.001. 
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Figure 45 Gfi1 mRNA Expression in Response to LPS +/- Cycloheximide in Wild Type BMDMs. 
BMDMs were pre-treated for 30 minutes with 10 µg/ml cycloheximide and then stimulated with 100ng/ml 
LPS as indicated for the stated times. Quantitative PCR of mRNA, with results normalised to expression of 
18s RNA and fold induction calculated relative to unstimulated expression. Error bars show the SEM of 4 
independent stimulations. A student’s t-test (2-sided) was performed on the results; NS is not significant;   
* p <0.05; ** p <0.01; *** p <0.001. 
 
 
 
 
 
 
 
 
 
Figure 46 Gfi1 mRNA Expression in Response to LPS and Zymosan +/- IL-10 in Wild Type BMDMs. 
BMDMs stimulation for 6 hours with 200µg/ml zymosan, 100ng/ml LPS and 100ng/ml exogenous IL-10 as 
indicated. Quantitative PCR of mRNA, with results normalised to expression of 18s RNA and fold 
induction calculated relative to unstimulated expression. Error bars show the SEM of 4 independent 
stimulations. A student’s t-test (2-sided) was performed on the results; NS is not significant; * p <0.05; ** p 
<0.01; *** p <0.001. 
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Gfi1 is highly expressed in response to TLR2 and TLR4 stimulation, but is not induced at 
all in response to zymosan. This is surprising, as we have previously seen zymosan is an 
incredibly potent activator of TLR2. We must therefore consider what effects on the 
macrophage that zymosan has in addition to being a TLR2 ligand, such as other PRR 
involvement (for example Dectin-1 signalling) or the process of phagocytosis that maybe 
involved in preventing Gfi1 up regulation in response to zymosan stimulation. To 
examine the hypothesis of phagocytosis preventing the upregulation of Gfi1 in response 
to zymosan, I stimulated macrophages with LPS and latex beads at the same time to try 
and mimic the co-activation of TLR and phagocytosis seen with zymosan. Figure 47 
shows that the combination of LPS and latex beads did significantly reduce the induction 
of Gfi1 when compared to LPS alone. This suggests that phagocytosis plays a significant 
role in the lack of Gfi1 induction in response to zymosan stimulation.  
 
To study Gfi1 further, I planned to knock down the protein using silencing RNA against 
Gfi1. Unfortunately my initial experiments showed that RAW264.7 cells, unlike 
BMDMs, do not express Gfi1 in response to LPS (Figure 48). This experiment was not 
attempted in BMDMs, because at the time we did not have a successful protocol for 
adequately transfecting primary macrophages. 
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Figure 47 Gfi1 mRNA Expression in Response to Zymosan, LPS and Beads in Wild Type BMDMs. 
BMDMs stimulation for 6 hours with 200µg/ml zymosan, 100ng/ml LPS and 20µl 0.8micron latex beads as 
indicated. Quantitative PCR of mRNA, with results normalised to expression of 18s RNA and fold 
induction calculated relative to unstimulated expression. Error bars show the SEM of 4 independent 
stimulations. A student’s t-test (2-sided) was performed on the results; NS is not significant; * p <0.05; ** p 
<0.01; *** p <0.001. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 48 Gfi1 mRNA Expression in Response to LPS in RAW264.7 Macrophage Cell Line. 
Raw264.7 cells were stimulated with 100ng/ml LPS for the stated times. Quantitative PCR of mRNA, with 
results normalised to expression of 18s RNA and fold induction was calculated relative to unstimulated 
expression. Error bars show the SEM of 4 independent stimulations.  
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 4.7.2 Cyclo-oxgenase 2 
Cyclo-oxgenase (COX) is also known as prostaglandin H-synthase and is the enzyme 
responsible for the rate limiting step in pro-inflammatory prostanoid biosynthesis. There 
are two distinct isoforms of COX, COX1 and COX2. COX1 is present constitutively in 
many tissues, whilst COX2 is present constitutively in very few tissues but can be 
induced by a variety of mediators such as cytokines, tumour promoters and bile acids 
(Seibert, Massferrer et al. 1995). The anti-inflammatory and analgesic effects of 
traditional nonsteroidal anti-inflammatory drugs (NSAIDs) such as aspirin, ibuprofen and 
diclofenac, are thought to be primarily due to the inhibition of inducible COX2, whereas 
the well known gastrointestinal side effects of NSAIDs are thought to be due to inhibition 
of COX1 (Massferrer, Zweifel et al. 1994). This lead to the development of selective 
COX2 inhibitors which were hoped to have therapeutic actions similar to traditional 
NSAIDs but without the GI side effects and are licensed for use in acute pain states and 
chronic rheumatological conditions (Shi and Klotz 2008).  
 
As COX2 is clearly involved in pro-inflammatory states and its inhibition is an 
efficacious clinical intervention, I decided to look at the induction of COX2 in response 
to LPS and zymosan. Figure 49 shows that COX2 is dramatically induced in response to 
both LPS and zymosan, but LPS induction reaches its peak at about 5 hours and then 
decreases whilst zymosan induced COX2 expression continues to increase beyond my 
last time point. This suggests that the initial induction process maybe similar, but there is 
a continuing stimuli with zymosan. I wondered if it was possible that the continued 
COX2 expression was in some way connected to the increased levels of IL-10 seen with 
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zymosan stimulation, as it is reported that IL-10 represses LPS induced COX2 mRNA 
levels. It is therefore possible that if IL-10 is not working correctly following zymosan 
stimulation, then it may not repress COX2 mRNA levels. This could be investigated 
further by examining COX2 mRNA levels following zymosan stimulation in the IL-10 
knockout BMDMs. 
 
As COX2 is responsible for prostaglandin production, and as prostaglandin E2 can 
repress cytokine production by BMDMs, I wondered if high COX2 levels were affecting 
zymosan induced cytokine production. To examine this further I performed a zymosan 
time course with and without a COX2 inhibitor (NS398) in wild type BMDMs (Figure 
50). This shows that the inhibition of COX2 does not make any significant difference on 
the induction of IL-10 nor the level of induction of pro-inflammatory cytokines IL-6 or 
TNFα. 
 
 
 
 
 
 
 
 150
Figure 49 COX2 mRNA Expression in Response to LPS and Zymosan in Wild Type BMDMs. 
BMDMs were stimulated with 200µg/ml zymosan or 100ng/ml LPS for the stated times. Quantitative PCR 
of mRNA, with results normalised to expression of 18s RNA and fold induction calculated relative to 
unstimulated expression. Error bars show the SEM of 4 independent stimulations. A student’s t-test (2-
sided) was performed on the results; NS is not significant; * p <0.05; ** p <0.01; *** p <0.001. 
 
 
 
 
 
 
 
 
 
Figure 50 Cytokine mRNA Expression in Response to Zymosan +/- COX2 Inhibitor in WT BMDMs. 
BMDMs were incubated for 1 hour with 10µM NS398 prior to stimulation with 200µg/ml zymosan for the 
stated times. a) Quantitative PCR of mRNA, with results normalized to expression of 18s RNA and fold 
induction calculated relative to unstimulated expression. Error bars show the SEM of 4 independent 
stimulations. A student’s t-test (2-sided) was performed on the results; NS is not significant; * p <0.05;     
** p <0.01; *** p <0.001. 
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4.8 Fungal Ligands Induce a Regulatory Macrophage 
Phenotype  
Macrophages have to play distinct roles during the inflammation, ranging from a pro-
inflammatory function immediately after infection, to an anti-inflammatory function 
during resolution. In addition, the macrophage response must be tailored to the type of 
pathogen encountered, and as a result of this macrophages have a very plastic gene 
expression phenotype that is able to change depending on the exposure to specific stimuli 
or combinations of stimuli. This allows the macrophage to mount the appropriate 
response, and has lead to the concept of macrophage polarisation. The most commonly 
used terms for describing macrophage phenotypes are “Classically Activated 
Macrophages” (also known as M1) which are activated by TLR stimulation and IFNγ, 
and “Alternatively Activated Macrophages” (also known as M2) which are 
predominately activated by IL-4 and IL-13. However, macrophage polarity is now treated 
more as a spectrum allowing recognition of other subtypes such as regulatory, wound 
healing and tumour associated macrophages that exhibit distinct but differing 
characteristics from simply M1 or M2 classic phenotypes (Mosser and Edwards 2008). 
 
It has been well documented that classically activated macrophages, for example 
macrophages that have been stimulated with LPS, produce high levels of IL-12 and 
modest levels of IL-10; whilst regulatory macrophages, for example macrophages that 
have been stimulated with LPS in the presence of immune complexes, produce low levels 
of IL-12 and high levels of IL-10. The cytokine profile seen in wild type BMDMs 
following zymosan stimulation shows the typical textbook profile for regulatory 
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macrophages, so I attempted to investigate whether fungal ligands were able to induce a 
regulatory macrophage phenotype by examining the presence of regulatory macrophage 
markers. 
 
To examine my experimental BMDMs I compared the expression of Light and SPHK1, 
two markers of a regulatory macrophage phenotype (Mosser and Edwards 2008), in 
response to LPS and zymosan (Figure 51). This demonstrated that BMDMs treated with 
zymosan express far more Light and SPHK1 mRNA than LPS treated BMDMs. To see if 
this was due to phagocytosis, I examined the regulatory macrophage marker expression in 
BMDMs co-stimulated with LPS and latex beads.  
 
Figure 52 shows that phagocytosis does not affect the induction of SPHK1 or LIGHT in 
response to LPS. We must therefore consider the differences in receptor activation 
between zymosan and LPS.  
 
To delineate the effects of Dectin-1 and TLR2 activation with zymosan, I examined Light 
and SPHK1 expression in wild type BMDMs subjected to SYK inhibition, as SYK is 
required for much of the downstream signalling from Dectin-1.  Figure 53 shows that in 
the presence of SYK inhibitor II or R406 both regulatory macrophage marker expressions 
are decreased in zymosan stimulated BMDMs. This suggests that the switch to a 
regulatory macrophage phenotype is Dectin-1 and/or SYK dependent.  
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Figure 51 Regulatory Macrophage Marker mRNA Expression in Response to LPS and Zymosan in 
Wild Type BMDMs. BMDMs stimulation with 200µg/ml zymosan or 100ng/ml LPS for the stated times. 
Quantitative PCR of mRNA, with results normalised to expression of 18s RNA and fold induction 
calculated relative to unstimulated expression. Error bars show the SEM of 4 independent stimulations. A 
student’s t-test (2-sided) was performed on the results; NS is not significant; * p <0.05; ** p <0.01; *** p 
<0.001. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 52 Regulatory Macrophage Markers mRNA Expression in Response to Zymosan, LPS and 
Beads in Wild Type BMDMs. BMDMs stimulation for 6 hours with 200µg/ml zymosan, 100ng/ml LPS 
and 20µl 0.8micron latex beads as indicated. Quantitative PCR of mRNA, with results normalised to 
expression of 18s RNA and fold induction calculated relative to unstimulated expression. Error bars show 
the SEM of 4 independent stimulations. A student’s t-test (2-sided) was performed on the results; NS is not 
significant; * p <0.05; ** p <0.01; *** p <0.001. 
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Figure 53 Regulatory Macrophage Markers mRNA Expression in Response to a Variety of Stimuli in 
Wild Type BMDMs +/- SYK Inhibitors. BMDMs incubated for 1 hour with inhibitors 4µM SYK 
inhibitor II or 10µM R406 prior to stimulation 8 hours with either 10µg/ml curdlan, 200µg/ml depleted 
zymosan, 100ng/ml LPS, 1µg/ml Pam3CSK4 or 200µg/ml zymosan. Quantitative PCR of mRNA, with 
results normalized to expression of 18s RNA and fold induction calculated relative to unstimulated 
expression. Error bars show the SEM of 4 independent stimulations. A student’s t-test (2-sided) was 
performed on the results; NS is not significant; * p <0.05; ** p <0.01; *** p <0.001. 
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5. Discussion 
I have shown that TLR2 and Dectin-1 ligands activate the major MAPK, p38, ERK1/2 
and JNK pathways in macrophages. It was observed that the Dectin-1 only stimuli 
produce an attenuated response in comparison to zymosan. This maybe explained by the 
synergistic effect described when TLR2 and Dectin-1 signals are combined following 
zymosan stimulation. Zymosan activation of p38, ERK1/2 and JNK in the Dectin-1 
knockout BMDM occurs, but is attenuated in comparison to the wild type. This supports 
the current theory of receptor synergy for zymosan (Ferwerda, Meyer-Wentrup et al. 
2008). 
 
Experiments with the Dectin-1 neutralising antibody and Dectin-1 knockout BMDM are 
conflicting for curdlan stimulation. While the Dectin-1 neutralising antibody completely 
prevents depleted zymosan activation of the MAPK pathways, it does not prevent curdlan 
from activating these pathways. However, in the Dectin-1 knockout BMDM we see no 
activation of the MAPK pathways following either depleted zymosan or curdlan 
stimulation. There is currently no clear explanation for this, but one possible suggestion is 
that the binding of the neutralising antibody to the Dectin-1 receptor may be affected by 
the stimuli added. For example, it could be possible that the addition of curdlan may 
disrupt the neutralising antibodies binding, if curdlan has a higher affinity for the Dectin-
1 receptor than the neutralising antibody.  
 
To further understand the signalling downstream of Dectin-1 I used SYK inhibitors to 
attempt to prevent all downstream signalling from Dectin-1. An initial in vitro kinase 
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specificity screen showed that only two of the six tested SYK inhibitors, SYK inhibitor II 
and R406, actually inhibit SYK significantly and specifically enough to be worth 
investigating further. This evidence was supported by finding that these were the only 
two SYK inhibitors that prevented activation of BCR signalling in A20 cells – a process 
that fundamentally requires SYK. When SYK inhibitors are used in wild type BMDMs 
we would expect that Dectin-1 only ligands curdlan and depleted zymosan would not be 
able to activate downstream signalling in the presence of SYK inhibition, but that LPS 
and to a certain extent zymosan, would be unaffected as these are both strong TLR 
ligands. In actual fact I show that while SYK inhibitor II is able to prevent signalling in 
response to Dectin-1 only ligands, R406 causes only a minor decrease in phosphorylation 
of ERK1/2, p38, p105 and TBK1, and that activation is significantly delayed in the 
presence of the inhibitor. This maybe due to the stability of R406, although this seems 
unlikely as R406 works efficaciously in vivo, or due to an off target effect on another 
kinase or phosphatase. AS LPS signals through TLR4, we might not expect to see any 
major difference in LPS stimulated BMDMs with the use of SYK inhibitors; however it 
has been reported that SYK is involved in the regulation of LPS induced TLR4 
endocytosis (Zanoni, Ostuni et al. 2011). This may explain why both SYK inhibitor II 
and R406 affect cytokine production following LPS stimulation. However, R406, and not 
SYK inhibitor II, also caused inhibition of activation of TBK1. Looking at the effect of 
SYK inhibitor II and R406 on cytokine expression and secretion in wild type BMDMs I 
show that pro-inflammatory cytokines are marginally reduced in the presence of SYK 
inhibitor II, but massively inhibited in the presence of R406 in response to TLR2, TLR4 
and Dectin-1 stimuli. This does not appear to be IL-10 dependent, as R406 actually 
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decreases the expression and secretion of IL-10 too.  In combination, these findings 
suggest that possible off target effects of R406 are responsible, as if it was a true 
consequence of SYK inhibition we would expect to see the same results with SYK 
inhibitor II, which is arguably a more specific and effective pure SYK inhibitor than 
R406. Interestingly, R406 is the active metabolite of fostamatinib, a drug currently in 
phase III clinical trials for the treatment of rheumatoid arthritis (McAdoo and Tam 2011), 
and it could well be that its efficacy in this setting is due to its effect on another off target 
kinase, such as TBK1, and not SYK. This could be investigated further by using the 
TBK1 inhibitor BX795 (Clark, Plater et al. 2009) in combination with the SYK inhibitors 
to see if there is a synergistic effect, or by using BX795 in the conditional SYK knockout 
BMDMs.  
 
To investigate signalling further downstream from Dectin-1 I attempted to identify the 
kinase responsible for ERK1/2 activation. For most stimuli, Raf-1 activates MEK1/2 
which activates ERK1/2 (Kolch 2000), however in response to TLR2 signalling the 
kinase Tpl2 is required to activate MEK1/2, which activates ERK1/2 (Das, Cho et al. 
2005). It is therefore possible that Tpl2 maybe involved in ERK1/2 activation in response 
to Dectin-1 signalling. Using the Tpl2 inhibitor SHN681, I have shown that ERK1/2 
phosphorylation is significantly reduced in response to zymosan, and completely blocked 
in response to depleted zymosan. However, in conflict with these findings are the data 
from the IkappaB inhibitor BIX02514, which blocks the activation of Tpl2 higher in the 
signalling pathway. This showed that the Dectin-1 only ligands curdlan and depleted 
zymosan can still activate ERK1/2 when IkappaB is successfully inhibited with 
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BIX02514, which suggests that ERK1/2 is activated by a non-Tpl2 dependent 
mechanism. The IkappaB inhibitor data is supported by my findings that Dectin-1 ligands 
can still activate ERK1/2 in Abin2 knockout BMDMs. Conclusively, the experiments 
with the Tpl2 knockout BMDMs show that Dectin-1 signalling results in the same 
intensity of ERK1/2 activation in wild type BMDMs as it does in the Tpl2 knockout 
BMDMs, and that the Tpl2 inhibitor SHN681 is still able to inhibit the activation of 
ERK1/2 in the Tpl2 knockout BMDMs. We suggest therefore that the kinase responsible 
for ERK1/2 activation downstream of Dectin-1 is not Tpl2, but is an unidentified off 
target effect of SHN681. It is possible that Raf-1 is the kinase involved in the activation 
of ERK1/2, however on stimulation of wild type BMDMs with PMA I show that the 
addition of SHN681 does reduce ERK1/2 phosphorylation, but does not block it 
completely. This suggests that in cells Raf is inhibited to some degree by SHN681, but 
not fully, and so another kinase is likely to be involved. To investigate further will be 
difficult as there are many isoforms of Raf-1, and as it is fundamental in many cellular 
processes Raf-1 has many self-regulating mechanisms to prevent either its inhibition or 
stimulation (Hall-Jackson, Goedert et al. 1999).  
 
To examine the signalling pathways even further downstream, we examined the 
differences between TLR and Dectin-1 signalling in the MSK1/2 knockout model. In the 
MSK1/2 knockout BMDM we see that in response to zymosan, after 4 hours stimulation, 
there is an increase in the induction and secretion of pro-inflammatory cytokines IL-12 
(p40) and TNFα, with an increase in the expression only of IL-6.This is in keeping with 
the data published previously on LPS stimulation. Looking at the anti-inflammatory 
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effectors in response to zymosan we see a significant decrease in the cytokine IL-10, but 
see no real change in the levels of the MAPK phosphatase DUSP1 in the MSK1/2 
knockout (data not shown). Comparing zymosan to LPS (from (Ananieva, Darragh et al. 
2008), the levels of DUSP1 induced by LPS or zymosan is of a similar magnitude and the 
duration of p38 activations are comparable too.  
 
The Dectin-1 only stimulations with curdlan or depleted zymosan in the MSK1/2 
knockouts show a very similar picture to zymosan, but with one main difference, in the 
level of expressed TNFα, which is actually less than the wild type in the MSK1/2 
knockouts whilst the level of secreted TNFα is still higher in the knockouts than the wild 
type.  
 
When we use the inhibitors PD184352 and SB203580 in combination to chemically 
inhibit MSK1/2, we see a decrease in mRNA expression and cytokine secretion of IL-6, 
TNFα and IL-10 in the BMDM in response to zymosan, curdlan and depleted zymosan. 
This enhanced effect of inhibitors over the knockout is not surprising, as ERK1/2 and p38 
may regulate cytokine production via MSK1/2 independent mechanisms in addition to the 
MSK1/2 dependent pathways, or it is highly possible that the inhibitors may also be 
having off target effects on other kinases involved in cytokine production.  
 
From the fungal stimulated MSK1/2 knockout BMDM Western blots, we see that the 
transcription factors CREB and ATF1 are not activated in the absence of MSK1/2. It has 
been shown that in response to LPS CREB phosphorylation at Serine133 and/or ATF1 
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phosphorylation is/are required for binding to the IL-10 promoter to allow maximal IL-10 
transcription (Ananieva, Darragh et al. 2008). I have shown that in response to zymosan 
the CREB Serine133 knock-in BMDMs express and secrete less IL-10 and more IL-12 
(p40) and TNFα than the wild type, but the differences seen are not as drastic as those 
seen in the MSK1/2 knockout. We were fortunate to be able to use MSK1/2 KO/CREB 
KI triple BMDMs to examine this further, finding that the action of knocking out 
MSK1/2 affected more than just CREB activation. Whilst the loss of CREB does account 
for some of the changes seen with MSK1/2 it is likely that MSK1/2 also activates other 
transcription factors, the prime candidate being ATF1. To examine this further, we could 
investigate the role of ATF1 in AFT1 knockout BMDMs, or even see if it is possible to 
make CREB KI/ATF1 KO mice to examine for other potential transcription factors 
involved.  
 
Now we must consider how the absence of MSK1/2 may cause these effects on the 
cytokines produced. It is possible that the increases in IL-12 (p40) and TNFα we observe 
in the MSK1/2 knockout BMDM is purely down to the decrease in levels of IL-10. This 
idea is supported by the data from the IL-10 knockout and IL-10/MSK1/2 triple knockout 
experiments, which also show that in IL-10 deficient BMDMs the production of pro-
inflammatory cytokines increases. However, the effect of the MSK1/2 knockout or IL-10 
knockout following zymosan stimulation is significantly smaller than the effect following 
LPS stimulation (Ananieva, Darragh et al. 2008), as it affects fewer pro-inflammatory 
cytokines and to lesser extent although the levels of IL-10 are decreased to the same 
level. It is possible therefore that IL-10 does not play such a large role in the suppression 
 161
of inflammatory cytokines following zymosan stimulation as it does with LPS. This is 
illustrated when I saturate wild type BMDMs with exogenous IL-10; I was unable to 
suppress zymosan induced pro-inflammatory cytokines significantly, whereas with pure 
TLR agonists, such as LPS or Pam3CSK4, exogenous IL-10 can almost fully suppress 
pro-inflammatory cytokines. IL-10 exerts its anti-inflammatory effects by inducing the 
JAK-STAT transcription factor pathways, with STAT3 being fundamentally required for 
IL-10 to be able to suppress pro-inflammatory cytokine production (Williams, Bradley et 
al. 2004). In the investigation into why IL-10 does not suppress pro-inflammatory 
cytokines in response to zymosan, I examined STAT3. Zymosan causes much greater 
STAT3 phosphorylation than LPS does, which in one way is expected as zymosan 
induces much more IL-10 than LPS does, but is surprising in another way, as you would 
imagine that increased STAT3 activation would result in more suppression of pro-
inflammatory cytokines. This could be explained if there was a threshold of STAT3 
activation that gave maximal effect, and any further activation does not correspond to 
more suppression, but this does not help explain why LPS suppresses pro-inflammatory 
cytokines more than zymosan. It is likely is that there are other factors at play. For 
example, we see that zymosan causes much greater phosphorylation of STAT5 than LPS 
does, and the possible role of STAT5 in macrophage cytokine production is not clear at 
present. 
 
 One significant difference we see between LPS and zymosan stimulations of 
macrophages is the level of induced Gfi1. As Gfi1 is a transcriptional repressor that is 
shown to be important in preventing over production of pro-inflammatory cytokines 
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(Karsunky, Zeng et al. 2002), it may well play a role in the differences seen between the 
effects of LPS and zymosan as we see large induction of expression in response to LPS 
but very little in response to zymosan. PIAS3 is a STAT3 inhibitor, able to bind to 
activated, phosphorylated STAT3 dimers and blocking their DNA binding ability 
(Chung, Liao et al. 1997). Gfi1 is reported to interact with PIAS3, reducing the inhibitory 
effect of PIAS3 on STAT3 activity and enhancing STAT3 signals (Rodel, Tavassoli et al. 
2000). In response to zymosan stimulation we see a large amount of STAT3 
phosphorylation, but very little Gfi1. It is therefore possible that without Gfi1 to inhibit 
PIAS3, PIAS3 is binding the activated STAT3 and not allowing it to bind to DNA. This 
would result in STAT3 being unable to function, and hence no repression of pro-
inflammatory cytokine expression would occur. This hypothesis could be tested in future 
work using Gfi1 knockout BMDMs, as it is a very plausible explanation for the inability 
of IL-10 to suppress zymosan induced pro-inflammatory cyokines, but leads to the 
question of why is Gfi1 expressed in response to LPS but not zymosan? 
 
I examined the mechanism of induction of Gfi1 by LPS further, showing that Gfi1 is 
activated by a secondary protein and not by LPS directly, and that IL-10 does not seem to 
be involved.  
 
In the quest to find out why IL-10 is ineffective at suppressing pro-inflammatory 
cytokines in response to zymosan stimulation we must remember that in fungal 
stimulation the particles undergo phagocytosis by the macrophage. It is entirely possible 
therefore that while the macrophage is full of pathogen it is not in the cells best interest to 
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resolve inflammation. To examine this hypothesis further we compared zymosan 
stimulation to a co-stimulation with latex beads and LPS. We found that phagocytosis 
and LPS does change the profile of expression of pro-inflammatory cytokines IL-6 and 
IL-12 p40, causing their levels to be reduced to the level of zymosan expressions, 
however unlike zymosan stimulation the addition of exogenous IL-10 still did 
significantly suppress these cytokines. This suggests a mechanism that is not simply the 
process of phagocytosis and concomitant TLR stimulation, and if I were to investigate 
further I would use LPS coated latex beads, as I have not accounted for any intra-
phagosomal signalling that maybe occurring when zymosan particles used. However, the 
findings with TNFα are interesting as LPS in combination with latex beads causes an 
increase in expression of TNFα, so it appears phagocytosis contributes to significantly 
further stimulating TNFα induction, although not to the same level as zymosan 
stimulation. In the same fashion, IL-1β is reduced to the level of zymosan induction in 
the presence of LPS and latex beads, and both TNFα and IL-1β inductions are 
unresponsive to the addition of exogenous IL-10. It is therefore possible that the process 
of phagocytosis is involved in IL-1β and TNFα expressions.  
 
In examining the different macrophage phenotypes induced by LPS and fungal signalling, 
we found that activation of Dectin-1 in a SYK dependent fashion resulted macrophage 
switching to a regulatory macrophage phenotype. This is very interesting, as regulatory 
macrophages are thought of as essentially anti-inflammatory, playing a role in resolving 
inflammation whilst still retaining the capacity for production of pro-inflammatory 
cytokines and adaptive recruitment if required (Mosser and Edwards 2008). If fungal 
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pathogens do promote a regulatory macrophage phenotype this may help explain why 
many people suffer commensal fungal infections that can persist for long periods of time 
(for example athletes foot) without developing the classical inflammatory signs of 
infection. 
 
One of the persisting findings during my study is that the Dectin-1 only ligands are less 
immunogenic than TLR agonists and as such causes a much lower induction of pro-
inflammatory cytokines. This may be because in vivo the role of initiating a large 
inflammatory response is due to TLR2, and that Dectin-1 is there not only to enhance this 
response, but also to provide a level of activation in response to commensal fungal 
pathogens. Perhaps this is why we see that knocking out Dectin-1 makes little difference 
to the clinical outcome of mice infected with virulent pathogens such as Cryptococcus 
neoformans and Pneumocystis carinii (Saijo, Fujikado et al. 2007). In these instances the 
Dectin-1 knockout mice respond in an identical manner to their wild type counterparts. 
However, when the Dectin-1 knockout mice are challenged with fungi that are prevalent 
in the environment, such as Aspergillus , they are unable to mount a satisfactory immune 
response (Werner, Metz et al. 2009). This is supported by the known human mutation in 
Dectin-1, as the patients whom have the mutation are at a much increase susceptibility to 
development of mucosal and cutaneous candidiasis, but do not succumb to systemic 
fungal infection (Ferwerda, Ferwerda et al. 2009). In conclusion, it seems that Dectin-1 is 
essential for initial anti-fungal defences at colonisation sites, but once the fungal 
pathogen enters the body systemically it is recognised and destroyed, either by innate 
recognition (especially via TLR2) or by the adaptive immune system.  
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